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Delivering molecular immunotherapies to the necessary organs is a frequent bottleneck in 
translating drugs to the clinic. We directly associate adjuvants to naked mRNA in an 
orthogonal fashion so that sufficient and directed immune responses are elicited against 
the expressed antigen. We then demonstrate two non-invasive approaches - one focused 
on imaging and the other on mucosal delivery - that attempt to inform the discussion of 
mRNA delivery in large mammals. To aid in the rational design of mRNA vaccines, we 
developed a dual PET/near-IR based approach to non-invasively monitor mRNA 
trafficking longitudinally with high spatio-temporal resolution in non-human primates. This 
dual imaging modality approach has the potential to link systemic scale events with cellular 
level details. We use this PET/CT based approach to monitor mRNA trafficking after 
transfection of the female reproductive tract (FRT) epithelium. Using antibody 
modifications, we can generate robust levels of the HIV broadly neutralizing antibody 
PGT121 that reach neutralizing concentrations within hours and persist for weeks in sheep 


















Using mRNA in therapeutic and vaccine applications is currently in vogue. Cost effective 
and robust production methods, excellent therapeutic index profiles, flexible and 
interchangeable design parameters, and fast production of encoded protein, make mRNA 
particularly attractive for transgene production in vivo. The biotech industry has taken note, 
and there are numerous independent companies and subsidiaries of larger ones, that 
focus exclusively on mRNA. While the promise is large and the field is moving quickly (as 
seen by the increase in mRNA clinical trials), there are numerous gaps in mechanism, 
design, immune interaction, and delivery that will undoubtedly require attention for 
downstream clinical applications.  
 
At the Santangelo lab, we bring light to these gaps in knowledge, while providing 
engineering platforms that assist in investigating them further. With the ability to monitor 
at the level of single molecules and cells, we are able to provide insight on spatial, 
temporal, and kinetic determinants of mRNA efficacy, at the cellular level (sub-cellular 
trafficking, transcript stability, innate immune sensors and activation, and cellular entry 
mechanisms) and from a systems level (biodistribution, targeted delivery to specific 
organs, and immune interactions). Because we always keep one eye on translationally 
relevant questions, a guiding principal of our work is simplification. The more moving parts 
a technique or formulation has, the probability increases for unforeseen interactions and 
complications in vivo, resulting in downstream regulatory approval hurdles.  
 
This thesis provides a chronological snapshot of some of the work I have pursued during 
my research. Although the projects are at first glance somewhat disparate, shared 
principals of simplification (orthogonal labeling of mRNA) and non-invasiveness (whole 
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body imaging, mucosal delivery) are evident throughout. I believe the implications of the 
work are quite powerful. As a result, the data and techniques presented here might 
generate just as many questions as they provide answers.  
 
• The first chapter will discuss a direct means to orthogonally conjugate immune 
adjuvants onto mRNA based vaccines, without use of carrier particles. Specific 
and tailored memory immune responses, both humoral and cellular, are elicited.  
 
• I will then describe a positron emission tomography (PET) based approach to 
monitor mRNA vaccine trafficking in the days following administration in non-
human primates (Chapter 2). The sensitivity of the technique is on the order of 
10ng of mRNA per mL.   
 
• Lastly, I will discuss my most recent work involving mucosal aerosol delivery of 
antibody encoding mRNA to the female reproductive tract of sheep and non-
human primates. Expression of high concentrations of antibody at the site of 
infection occurs within a few hours, resides in tissue for at least a month, and 
functionally neutralizes virus.  
 
I promise to you the reader that I will resist my loquacious side and present the information 
in a succinct manner. As the third project is still a work in progress, I will also be upfront 
of what remains to be completed in future studies.  
 







Synthetic mRNA uses for therapeutic and vaccination purposes 
 
The use of mRNA as a biotechnology for therapeutic purposes has exploded in recent 
years, directly benefitting from the mechanistic insights garnered from siRNA therapy 
development and production scale increases through Good Manufacturing Practices 
(GMP).  There are tens of clinical trials that are ongoing or have been completed that use 
mRNA as a therapeutic, and numerous pharmaceutical companies have entered this 
blossoming field.  
 
Although they have received the great majority of focus and attention since 1990 when 
Wolf et al demonstrated in vivo delivery of plasmid DNA and mRNA1, translational DNA 
vaccine approaches have been limited by low immunogenicity in humans compared to 
animal models and AAV initiated immune response against the vector itself. As a vaccine, 
mRNA has intrinsic advantageous attributes that make it attractive: an excellent safety 
profile due to transient protein expression with naturally occurring cellular breakdown 
pathways; no possibility of nuclear insertion; cellular processing that mimics viral 
transcripts; robust, cell free production methods; rapid manufacturing - on the order of 
days to respond to need; flexibility in delivery by viral, non-viral, or cellular vectors; focused 
immune responses to specific epitopes, similar to subunit vaccines2 ; and perhaps most 
critically, mRNA vaccines have displayed induction of humoral and cell-mediated immunity 
in numerous disease models.  
 
Some other benefits of mRNA, include:  
 mRNA can be manufactured without use of cells: this allows rapid mRNA synthesis at 
scale and cost. This also confers a certain flexibility, as all aspects of the process (i.e. 
modified nucleotide bases) can be controlled. Compare this to proteins and viruses, which 
require in vitro expression in cells with downstream purification.  
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 Protein expression within 4 hours: this is in contrast to DNA plasmid based methods 
that have peak expression times around 36 hours. RNA peak expression occurs at around 
12 hours.  
 Expression is transient and self-limited: depending on the application, if we don’t want 
the encoded protein expression for months or years.  
 Stable storage at room temperature: in lyophilized form, RNA can be stably stored for 
years without negatively impacting mRNA function. Compare this to protein, which must 
be stored in cold chain storage conditions to maintain stability.  
 Glycosylation patterns follow that of the host: since host cells are translating the 
synthetic mRNA, post-translational modifications will also be included in the final form of 
the expressed protein.  
 
When IVT mRNA is delivered, a characteristic innate response pattern is elicited.  This 
innate response stimulation is mainly due to mRNA interacting with anti-viral sensors 
located in endosomal compartments (TLRs) and other receptor families in the cytoplasm 
( RIG-I-like receptors (RLRs) and NLRs). These pattern recognition receptors (PRRs) vary 
not only in cellular compartment, but also in the mRNA elements they recognize. Although 
mRNA is single stranded by design and as such is recognized by ssRNA detectors TLR7 
and TLR8, hairpins in the secondary structure can result in dsRNA segments that bind 
TLR3. In a similar manner, cytoplasmic PRRs recognize both ssRNA and dsRNA 
elements. The degree of innate immune stimulation can be controlled through the use 
modified uridine bases. This innate immune abrogation is demonstrated in Chapter 1.  
 
With the ability to tune the intrinsic immunogenicity of synthetic mRNA, it can be used for 
purposes of protein replacement therapy, or as a vaccine. In the case of protein 
replacement therapy, the goal is to express the encoded protein, without immune 
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stimulation, as innate immune responses will shut down translation, decreasing the 
ultimate amount of encoded protein expressed by cells. Thus, protein expression should 
be maximized and immunity minimized. In the case of vaccines, a balance between 
translation of encoded antigen and innate immune stimulation is required. If the innate 
stimulation is too low, then the immune response will not be robust enough to establish an 
adaptive immune response. In a similar manner, if innate stimulation is too high, then not 
enough antigen expression will occur for establishment of adaptive immune responses. 
Table 1 lists numerous applications where mRNA is being utilized, both as a therapy and 

































Table 1: Therapeutic mRNA applications. This table lists numerous approaches and 
applications that are currently being investigated using synthetic mRNA. Table is from: 
Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of 









Throughout this thesis, the 3’UTR of the synthetic mRNA is used to anneal oligos that 
contain adjuvants (Chapter 1), dyes (Chapter 2), or radionuclides (Chapter 2 and 3). This 
binding to the UTR occurs without inhibition of mRNA translation potential (Chapter 2). 
We prefer this direct method of RNA labeling because it allows us to work with, but not be 
dependent on the use of particles and carrier proteins during delivery. In fact, I hope after 
reading this thesis that it becomes clear these carriers are not nearly as required as might 
be assumed. In our mind, naked synthetic mRNA facilitates the transition from the bench 




























Tuning the immune response to synthetic mRNA 
 
 
The work presented here is under consideration as:  
In vitro transcribed messenger RNA vaccines with programmable stimulation of 
innate immunity. Kristin H. Loomis†a, Kevin E. Lindsaya, Chiara Zurlaa, Sushma M. 
Bhosle, Daryll A. Vanover, Emmeline L. Blanchard, Jonathan L. Kirschman, Ravi V. 
Bellamkonda††, Philip J. Santangelo*  
a The authors contributed equally  
Summary 
 
In vitro transcribed (IVT) mRNA is an appealing platform for next generation vaccines, as 
it can be manufactured rapidly at large scale to meet emerging pathogens. However, its 
performance as a robust vaccine is strengthened by supplemental immune stimulation, 
which is typically provided by adjuvant formulations that facilitate delivery and stimulate 
immune responses. Here, we present a strategy for increasing translation of a model IVT 
mRNA vaccine while simultaneously modulating its immune-stimulatory properties in a 
programmable fashion, without relying on delivery vehicles, which we believe will allow for 
more controlled and standardized vaccination studies. Substitution of uridine with the 
modified base N1-5-methylpseudouridine reduces the intrinsic immune stimulation of the 
IVT mRNA while enhancing antigen translation. Tethering adjuvants to IVT mRNA through 
antisense nucleotides boosts the immuno-stimulatory properties of adjuvants in vitro, 
without impairing transgene production or adjuvant activity. In vivo, intramuscular injection 
of tethered IVT mRNA-TLR7 agonists leads to enhanced local immune responses, and to 
antigen-specific cell-mediated and humoral responses. This system represents a potential 
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platform compatible with any adjuvant of interest and it enables specific programmable 
stimulation of immune responses. 
Background 
 
Long manufacturing-times associated with current vaccine development impede rapid 
responses to quickly mutating and emerging pathogens. Synthetic messenger RNA 
produced via in vitro transcription (IVT mRNA) is a platform for next generation vaccines 
that has the capacity for rapid and large-scale manufacturing. As a vaccine, mRNA 
presents several attractive advantages: an excellent safety profile due to transient protein 
expression within hours of delivery, no nuclear insertion, cellular processing that mimics 
viral transcripts, immune responses to specific epitopes, and, most critically, induction of 
humoral and cell-mediated immunity 2–5. IVT mRNA vaccines have recently been 
investigated in pre-clinical studies for several diseases, including influenza 6,  Zika 7, and 
cancer 8. Several anti-cancer mRNA vaccines have entered clinical trials, where the ease 
of manufacturing enables personalized treatment. However, no formulation has of yet 
significantly improved patient outcomes 8. 
 
IVT mRNA delivered to host cells is translated by the cellular machinery into antigenic 
proteins. Concurrently, IVT mRNA activates pattern recognition receptors (PRRs) that 
have evolved as anti-viral RNA sensors to detect single and double-stranded transcripts.  
In general, PRRs can be classified according to their location within the cell: Toll-like 
receptors (TLRs) 3, 7, and 8 bind ssRNA and dsRNA in the endosomal compartment 9,10, 
while cytoplasmic detection largely relies on RIG-I like receptors (RLRs) and Nod like 
receptors (NLRs).TLR signaling causes translocation of pro-inflammatory transcription 
factors (ie NF-kappaB, IRF7, IRF3) to the nucleus, ultimately releasing Type 1 IFNs and 
pro-inflammatory cytokines 3,11. These secreted IFNs and cytokines act in an autocrine 




TLR expressing antigen-presenting cells (APCs) such as dendritic cells (DCs) and 
macrophages are the orchestrators of the innate immune response and are also 
responsible for linking the innate and adaptive immune responses upon migration to 
draining lymph nodes and activation of T and B cells. The type of antigen specific effector 
and memory responses that are generated largely depend on the cytokine profiles 
released by cells during the innate response: for example IL12 and IFNγ promote TH1 and 
cytotoxic T lymphocyte (CTL) pathways, while IL4 and IL6 promote humoral responses 12. 
 
mRNA has characteristic innate immune response profiles with a demonstrated intrinsic 
adjuvant ability. Unmodified IVT mRNA has been shown to elicit robust type I interferon 
responses 13,14, which can activate protein kinase R (PKR) and 2'-5'-oligoadenylate 
synthetase like (OAS-L), resulting in reduced antigenic protein levels 15 as a consequence 
of protein translational inhibition and RNA decay. High interferon responses have also 
been linked to weak cell-mediated immunity  using  both an interferon alpha receptor  
knockout animal model 13 as well as an animal model treated with an interferon receptor-
blocking antibody 14.  
 
As the innate immune responses elicited for an IVT mRNA vaccine influence the yield of 
antigenic protein as well as the nature of specific memory immune responses, there has 
been a significant effort to study the intrinsic immunogenicity of IVT mRNA and the use of 
adjuvants in vaccine formulations to modulate immunogenicity. Substitution of uridine with 
the modified bases pseudouridine (Ψ) 16,17 or N1-5-methylpseudouridine (M1Ψ) 18,19 in IVT 
mRNA has been shown to reduce innate immune activation and to increase transgenic 
protein synthesis. However, reduced innate immune responses to modified IVT mRNAs 
often required the use of specific adjuvants to grant supplemental immunogenicity by 
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controlling innate cytokine release 20. The potential benefits of utilizing adjuvants include 
dose and frequency reduction, vaccine response broadening, rapid response, and 
overcoming immune senescence 21.   
 
To date, the prevailing approach for complexing adjuvants with nucleic acids is using 
cationic carriers such as protamine or nanoparticles. For example, researchers at 
CureVac demonstrated the efficacy of an influenza vaccine consisting of a naked antigen 
encoding mRNA (unmodified RNA) and mRNA associated with protamine, which resulted 
in both B and T cell-mediated responses 22,23. Another recently reported M1Ψ modified IVT 
mRNA vaccine against the Zika virus utilized a cationic lipid nanoparticle as a delivery 
vehicle.  Different disease target for IVT mRNA vaccination may require the development 
of unique adjuvant and delivery formulations to yield protective immune responses. The 
main challenge in the successful design of IVT mRNA vaccines is the development of a 
versatile platform able to grant high antigenic protein expression while inducing controlled 
and specific robust memory immune responses. Ideally, this strategy should not rely on 
any delivery vehicle formulation to allow for a controlled and uniform stimulation of the 
immune system.  
 
In this study, we describe an IVT mRNA-based vaccine platform that enables modular 
tethering of small molecule adjuvants for a programmed stimulation of innate immunity 
that does not solely rely on delivery vehicle formulations. An IVT mRNA encoding for the 
well-established cytoplasmic ovalbumin antigen (OVA) was selected as a model vaccine. 
To tether small molecule agonists to IVT mRNA, we modified the multiply-labeled 
tetravalent RNA imaging probes (MTRIPs) design pioneered by Santangelo et al. 24. 
MTRIPs (multiply labeled tetravalent RNA imaging probes) consist of four RNA-targeting 
2’-O-Methyl based oligonucleotides assembled on a neutravidin core. MTRIPs were 
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utilized in the last decade to study endogenous 24–31 and exogenous RNA 15,32 dynamics 
via fluorescence microscopy without hindering translation or affecting stability 15. Here, we 
generated monovalent MTRIPs (mMTRIPs) by covalently linking single RNA-targeting 
oligonucleotides to free amines on a Neutravidin core. Four different oligos were selected, 
each targeting a different region in the 3’ UTR of the IVT mRNA. We confirmed that 
mMTRIPs hybridization to IVT mRNA did not significantly influence transgene production 
nor alter innate immune activation. Previous studies demonstrated that the available biotin 
binding sites can be utilized to perform an array of reactions, such as strand displacement 
and exchange 33. Here, the four available biotin binding sites on the neutravidin core were 
utilized to conjugate biotinylated adjuvants, offering a flexible platform for the delivery of 
small molecule agonists. To selectively stimulate TLR2 and TLR7 pattern recognition 
receptors we utilized two well-characterized small molecule agonists. The TLR2 agonist 
PAM2CSK has been found to drive development of Type 2 helper T cell responses 34,  
promote T helper cell longevity, and reduce the activation threshold for T cell receptor 
activation 35–37.  TLR7 agonists – in this case CL264 -  enhance Type 1 helper T cell and 
cytotoxic T cell responses 38,39.  TLR7 activation has been shown to enhance the 
immunogenicity of influenza 40,41 and other vaccines 39,42,43.  
 
First, we abrogated the intrinsic innate response profile of OVA mRNA in vitro through 
M1Ψ base incorporation, which also led to enhanced production of the transgene protein. 
Next, we demonstrated that tethering TLR agonists to mRNA can stimulate either the 
extracellular PRR TLR2 or the endosomal PRR TLR7 in vitro in transfected RAW264.7, a 
murine-derived macrophage cell line used as a model system, as it produces robust 




Last, we monitored the cellular and humoral immune responses following murine 
intramuscular (i.m.) injection of TLR7 agonists tethered to IVT mRNA. Since APCs, which 
should ideally be targeted and activated, have a strong proclivity for naked mRNA uptake 
upon intramuscular or intradermal injection, no carriers or formulations were utilized for 
delivery. We demonstrated that agonist-tethered mRNA increased innate immune 
responses and resulted in OVA antigen specific cell mediated and humoral responses.    
 
Our results indicate that this strategy enables stoichiometric control of the nucleic acid to 
adjuvant ratio, offering a more robust innate immune stimulation than mRNA and 
adjuvants delivered as a cocktail (i.e. untethered), likely because of a local increase of the 
adjuvant’s concentration at the site of injection. This promotes a stronger and longer-
lasting localized effect. This system enables specific programmable stimulation of immune 
responses and represents a platform potentially compatible with any adjuvants of interest 
for future IVT mRNA vaccine design readily applicable to intramuscular delivery. 
 
Effects of modified uridine base substitutions on protein expression and 
immunostimulatory properties of IVT mRNA 
We first aimed to attenuate the innate response profile induced by mRNA transfection, 
while maintaining high protein expression in vitro. Substitution of uridine with the modified 
bases pseudouridine (Ψ) 16,17 or N1-5-methylpseudouridine (M1Ψ) 18,19 in IVT mRNA can 
reduce innate immune activation and increase transgenic protein synthesis. We therefore 
synthesized three OVA expressing IVT mRNAs identical in sequence but incorporating 
either unmodified bases, or substituting Ψ or M1Ψ for uridine. To evaluate innate immune 
activation, RAW 264.7 macrophage cells were transfected with IVT mRNA using 
Lipofectamine 2000 (L2K), and total RNA was isolated and assayed for gene expression 
using a mouse antiviral qRT-PCR array. This array consists of primer assays for genes 
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associated with immune responses to exogenous RNA, such as viral RNA. As expected, 
IVT mRNA composed of unmodified bases led to the highest upregulation of interferon 
signaling and stimulated genes, while IVT mRNA incorporating M1Ψ was less immune-
stimulatory than IVT mRNA incorporating Ψ (Figure 1.1 A-C).  Specifically, broad and 
potent interferon signaling and response genes, including IFNα2, IFNβ1 and Mx1, were 






Figure 1.1: Effects of modified uracil base substitutions in IVT mRNA on cellular 
innate immune responses and transgene production. (A) Heat map showing gene 
expression of RAW264.7 cells following transfection with OVA IVT mRNA composed of 
unmodified bases (AUGC), and incorporating either pseudouridine (AΨGC), or 1-methyl 
pseudouridine (Am1ΨGC). IVT mRNA was delivered using Lipofectamine-2000. Gene 
expression for each condition is shown as a fold increase over cells treated with 
lipofectamine only (L2K). Fold increases of (B) common interferon signaling genes: 
interferon alpha 2 (Ifna2), interferon alpha receptor 1 (Ifnar1), interferon-beta 1(Ifnb1) and 
(C) interferon stimulated genes: inerleukin-15 (Il15), Ubiquitin-Like Modifier (Isg15), and 
MX Dynamin-Like GTPase 1 (Mx1). 95% confidence intervals are shown and * indicates 
that expression was significantly different from L2K control. (D and E). RAW264.7 cells 
were transfected with OVA IVT mRNA with the indicated nucleobase composition using 
Lipofectamine 2000.  At the indicated time points, cells were stained for the ovalbumin 
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protein and analyzed with flow cytometry.  (D) shows the percentage of cells expressing 
ovalbumin protein and (E) shows the median fluorescence of the cells positive for protein 
expression. Error bars indicate standard deviation (n=3) 
 
We used flow cytometry to determine the impact of uridine substitution on ovalbumin 
protein expression following transfection (Figure 1.1D-E). The highest percentage of cells 
positive for transgene protein production and the highest median fluorescence intensity 
were observed upon transfection of M1Ψ IVT mRNA. While the majority of studies indicate 
that substitution with Ψ enhances transgene protein production 16,17,45, we found that Ψ 
IVT mRNA led to slightly less transgene protein levels compared to unmodified IVT mRNA. 
The influence of modified bases, particularly Ψ, may depend on the gene of interest, codon 
optimization algorithms, as well as particular experimental conditions, such as the 
transfected cell type. The ability to achieve a minimal level of mRNA-induced innate 
immune activation is advantageous to address the effect of specific TLR agonists and to 
modulate activation of innate receptors, while retaining enhanced protein expression. 
Therefore, M1Ψ- IVT mRNA was utilized for all subsequent studies. 
 
Assembly and in vitro characterization of adjuvant-tethered IVT mRNA 
 
As innate responses in vaccination are important for driving the nature of memory immune 
responses, we devised a strategy to supplement the intrinsic immunogenicity of the M1Ψ- 
IVT mRNA molecule by tethering to it a payload of adjuvants.  The overall approach is 
described in Figure 1.2. mMTRIPS were synthesized by designing four 2’O-methyl 
RNA/DNA chimeric oligonucleotides complementary to the 3’UTR of the ovalbumin IVT 
mRNA. These oligos contained terminal thiol groups, which were covalently bound to free 
amines present on Neutravidin using Solulink chemistry. The reaction was optimized to 
yield an oligonucleotide:Neutravidin molar ratio of 1:1, as determined by bicinchoninic acid 
assay (BCA) protein assay and nucleic acids absorbance at 260 nm. Biotinylated small 
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molecule agonists were conjugated to the Neutravidin-oligo complexes, the resulting 
mMTRIPS were purified via filtration, and hybridized to the IVT mRNA. To determine the 
efficiency of small molecule tethering, we used a biotinylated fluorescent dye.  Following 
purification, the overall fluorescence and 260 absorbance of the sample were measured 
and compared to a standard curve of known molar concentration of pure dye. We 
determined that, on average, 10 fluorescent molecules were bound to an IVT mRNA, 
which indicates that each RNA is labeled by approximately 2.5 mMTRIPS. The inclusion 
of modified bases in the IVT mRNA did not significantly affect mMTRIPS tethering 
efficiency 15.   
 
Figure 1.2: Schematic procedure for tethering small molecule agonists to IVT 
mRNA. (A) 2’O-Methyl RNA/DNA chimeric oligonucleotides complementary to the 3’ UTR 
of IVT mRNA and bearing a 5’ thiol group were covalenty linked to Neutravidin via Solulink 
chemistry to generate mMTRIPS. Unbound oligonucleotides were removed with 
centrifugal filtration.  (B) mMTRIPS were incubated with biotinylated small molecule 
agonists (purchased commercially).  Unbound biotinylated adjuvants were removed by 
centrifugal filtration. (C) Adjuvant-tethered oligonucleotides were hybridized to IVT mRNA. 
Unbound oligonucleotides, small molecules, or free Neutravidin, were removed by 
filtration.  
 
While mMTRIPs are composed of 2’OMethyl RNA/DNA chimeric nucleic acids, which 
typically abrogate immune responses 46,47, they could potentially alter the secondary 
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structure of the IVT mRNA leading to TLR7 activation. Thus, unmodified or M1Ψ modified 
IVT mRNA were delivered to RAW264.7 cells with or without tethered mMTRIPs and TLR7 
activation was quantified. Upon activation, TLR7 forms a protein complex termed the 
myddosome, which includes myeloid differentiation primary response gene 88 (MYD88), 
and interleukin-1 receptor-associated kinase proteins (IRAK1, IRAK2, IRAK3, and IRAK4), 
that initiates signaling cascades. TLR7-IRAK4 interactions were quantified with a proximity 
ligation assay 48 (PLA) as an indication of TLR7 activation after IVT mRNA delivery (data 
not shown). As expected, unmodified IVT mRNA upregulated TLR7 with respect to the 
L2K only control condition, while the M1Ψ IVT mRNA did not. However, no statistically 
significant differences in TLR7 activation were observed between unlabeled and mMTRIP-
labeled mRNA, indicating that mMTRIPs hybridization does not affect TLR7 activation. 
Thus, we expected that innate immune activation observed upon delivery of adjuvant-




Figure 1.3: Tethering TLR2 and TLR2/6 adjuvants to IVT mRNA does not alter 
adjuvant and IVT mRNA functionality. RAW264.7 cells were transfected with M1ψ OVA 
IVT mRNA and small molecule agonists using Lipofectamine 2000. Five hours following 
transfection, cells were fixed, permeabilized, stained for the genetically delivered 
ovalbumin protein, and then analyzed with flow cytometry (A-D) The percent of cells 
transfected as well as the median fluorescence intensity of cells positive for ovalbumin are 
shown. Error bars indicate standard deviation, (n=3). Each experiment was repeated at 
least twice with similar results. cellular responses to tethered adjuvants were assayed 
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using a RT-qPCR assay for IL-1β (E-F) Tethered and cocktail delivery of (E) CL264 and 
(F) Pam2CSK4 led to a marked upregulation of IL-1β transcripts compared to controls. 
Fold changes are shown normalized to a Lipofectamine only condition and are calculated 
using β- Actin as reference. (n=3). Error bars show 95% confidence intervals. *Indicates 
significant (p<0.05).  
 
The ability of adjuvant-tethered IVT mRNA to interact with its respective pattern 
recognition receptors while maintaining its translational efficiency was then assessed in 
L2K transfected RAW264.7. To demonstrate the flexibility of this platform two 
representative small molecule TLR agonists were chosen: CL264 (TLR7-specific) and 
PAM2CSK4 (TLR2-specific). TLR7 is expressed in the endosomal compartment and is a 
natural sensor of exogenous mRNA, while TLR2 is expressed on the plasma membrane 
where it binds extracellular lipopeptides common in bacteria and fungi. As expected, 
tethering either CL264 or PAM2CSK4 to IVT mRNA did not affect the translational 
efficiency of the IVT mRNA with respect to a cocktail formulation (untethered adjuvants) 
in transfected cells, as assayed via flow cytometry (Figure 1.3A-D). To verify that mRNA 
tethering did not inhibit agonist function, we measured IL1β mRNA production as an 
indicator of TLR signaling five hours post-transfection using RT-qPCR (Figure 1.3E). 
CL264-tethered IVT mRNA led to increased IL1B gene expression compared to mRNA 
alone, and to comparable levels than a cocktail delivery (not tethered). Instead, 
PAM2CSK4-tethered mRNA induced a dramatic upregulation of IL-1B expression, 
compared to the cocktail formulation. The IVT mRNA likely acts as a scaffold, 
concentrating PAM2CSK4 at the cell surface, facilitating receptor binding and increasing 
downstream signaling responses. Additionally, the inherent immune-stimulation profile of 
IVT mRNA may act synergistically with TLR2 activation to enhance innate immune 
signaling. In the case of CL264, the comparable levels of IL1B mRNA between cocktail 
and tethered conditions may be due to TLR7 localization in the endosomal compartment, 
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Tethering adjuvant to IVT mRNA induces an acute innate response upon 
intramuscular injection 
We investigated if agonist-tethering to IVT mRNA would lead to stronger innate immune 
responses than a cocktail formulation following i.m. injection in a murine model system. 
We reasoned that, upon i.m. injection, a cocktail formulation would elicit an effectively 
weaker immune response, because the small molecule adjuvants should readily diffuse 
away from the injection site, given their negligible molecular weight (e.g. CL264 is 413.43 
Da and PAM2CSK4 is 1271.85 Da). On the contrary, tethering to IVT mRNA, whose 
uptake is mediated by clathrin-mediated endocytosis 49, may promote its retention at the 
site of injection, and increase interactions with endosomal TLRs upon internalization, 




Figure 1.4: Gene expression in mice anterior tibialis muscle five hours following 
IVT-mRNA injection. (A) Heat map showing fold changes of gene expression over a 
sham injection control.  (B-H) Fold increase of gene expression of Toll-like responsive 
genes. Each data point indicates expression levels in an individual animal. Lines indicate 
the mean expression level. * indicates p<0.05, Student’s t-test based on the 2-ΔCT values 




To assess this, we injected i.m. M1Ψ IVT mRNA with tethered Cl264 or as a cocktail (five 
mice were used per experimental condition). M1Ψ mRNA and CL264 were also injected 
independently as controls. Five hours post injection, muscles were isolated and analyzed 
for local gene expression using a mouse antiviral qRT-PCR array (Figure 1.4 and 
Supplementary Figure 1.3). The heat map of gene expression in Figure 1.4A shows that 
injection of M1Ψ IVT mRNA alone and with Cl264 administered either in a tethered or 
cocktail formulation led to substantial but comparable upregulation of antiviral genes. As 
CL264 is a TLR7 agonist, we examined the expression of the Toll-like responsive genes 
in the array to gain insight into CL264’s role in upregulating gene expression (Figures 
1.4B-H). Contributions to the local immune response due to either CL264 or M1Ψ IVT 
mRNA stimulation relative to a sham control are reported in Figure 1.5A-B. To highlight 
how delivery of CL264 (tethered or cocktail) affected gene expression, results were 
normalized by the M1Ψ mRNA control (Figure 1.5C-D). IL1β and Nlrp3, displayed a 
significant upregulation that was not observed in control conditions. IL1β promotes 
canonical pro-inflammatory mechanisms at the site of injection, including vasodilation, 
neutrophil and monocyte recruitment, and activation of matrix proteases 50. NLRP3 
associates with caspase-1 and adaptor proteins to form the inflammasome, a multiprotein 
complex that proteolytically activates pro-IL1 β, and is also directly involved in sensing 
cytoplasmic mRNA 51. Slight expression increases, although not statistically significant 
from the cocktail formulation, were also observed for pro-inflammatory cytokines IL6 & 









Figure 1.5: Gene expression in the mice anterior tibialis muscle five hours after i.m 
injection of CL264-tethered IVT mRNA. These data, summarized in Figure 4(A), are 
presented here to better visualize differences between individual treatment groups. 
Dashed lines indicate a fold regulation cut-off of 3. Listed genes are 3-fold over or under 
expressed with respect to control condition. * indicates gene expression was statistically 
different between the groups, p<0.05, Student’s t-test based on the 2-ΔCT values for each 
gene (n=5). + indicates gene expression is significantly different between Cl264 –tethered 





Adaptive responses to adjuvant-tethered mRNA indicate robust Th1 mediated and 
humoral immunity 
We hypothesized that a localized innate immune stimulation at the site of injection via 
CL26-tethering to IVT mRNA would facilitate the development of memory immune 
responses.  To assess this, we immunized mice with M1Ψ IVT OVA mRNA with and 
without tethered CL264 via i.m. injection. Mice also received a sham injection of the 
vehicle-only or M1Ψ IVT mRNA alone as control conditions.  Mice were immunized on day 
zero and a booster was administered on day 23. On day 41, murine splenocytes and 
serum were collected to assess antigen-specific memory immune responses. To evaluate 
the development of cell-mediated immune responses, an OVA-specific enzyme linked 
immunospot assay (ELISPOT) was utilized. The OVA peptide SIINFEKL, a potent MHCI 
epitope commonly used to detect potent CD8+ cytotoxic T cell responses, was tested as 
a positive control. Ex vivo splenocytes from tethered Cl264-mRNA vaccinated animals 
demonstrated a significant (p = 0.035) cell mediated response, as indicated by IFNγ 
release (Figure 1.6a). Splenocytes stimulated with whole ovalbumin yielded a less 
substantial (p = 0.09), yet similar TH1 cell-mediated response (Figure 1.6b). Accordingly, 
the number of IL-4 producing cells decreased, although non-significantly, suggesting a 
concurrent inhibition of the TH2 immune response (Figure 1.6c), which corroborates the 
inverse relationship between TH1 and TH2 immune responses.  Next, we analyzed the 
humoral immune response in the serum extracted from the same animals by measuring 
the concentration of anti-OVA specific IgG in sera using enzyme-linked immunosorbent 
assay (ELISA). All 5 animals that received tethered Cl264-mRNA formulations contained 
detectable levels of anti-OVA IgG, with an average concentration 8-fold higher than those 
treated with a cocktail formulation (Figure 1.6d). The elicited OVA-specific adaptive 
responses suggest that tethering adjuvants to IVT mRNA strongly increases mRNA 




Figure 1.6: Cellular and humoral immune responses elicited by IVT mRNA tethered 
to CL264 agonists. Mice were vaccinated i.m. twice with CL264-IVT mRNA (week 0 and 
week 3).  On week six, splenocytes and serum were harvested for analysis. (A-C) OVA 
specific cell-mediated immune response as measured by ELISPOT. Dissociated 
spleenocytes were plated in wells containing capture antibodies for either IFN-gamma (A-
B) or Il-4 (C) and tested for antigen specific immmune responses via stimulation with 
OVA257-264 SIINFEKL peptide (A) or whole OVA (B-C). Boxes represent the IQR, horizontal 
lines the median, and crosses the mean. *, P < 0.05. (D) anti-OVA specific IgG (ug/mL) in 
the serum at the time of sacrifice. Values were calculated from a standard curve via direct 
ELISA with plates coated with OVA. Values represented as mean with 95% confidence 








Here, we described a novel approach for the development of IVT mRNA-based vaccines 
that does not rely on delivery vehicles for immune stimulation. While delivery vehicles 
provide control over vaccine characteristics (e.g. conferring IVT mRNA protection from 
nucleases or cell-type specific delivery), they are not immunologically inert. Moreover, 
carrier’s delivery characteristics and efficiency are intimately tied to their immunological 
stimulation properties.  For example, size, shape, and charge of delivery vehicles have 
been found to affect both cell type uptake and immunological stimulation 52,53. Critically, 
activation of the innate immune response should be finely controllable, because it directly 
determines the nature of subsequent downstream adaptive responses. 
 
We demonstrated that naked M1Ψ IVT mRNA, characterized by an intrinsically low 
immunogenicity, can be delivered i.m. with a tethered payload of adjuvants in vivo leading 
to an enhanced local innate immune response at the injection site that ultimately results 
in enhanced antigen-specific cell-mediated and humoral immunity. Tethering small 
molecules adjuvants to the much larger mRNA likely decreases its diffusion away from the 
injection area, while raising its local concentration at the injection site and promoting 
interactions with PRRs. This potentially may represent a strategy to lower the systemic 
toxicity associated with numerous adjuvants 54. 
 
In summary, we present an orthogonal mRNA vaccine platform that directly associates 
adjuvants with IVT mRNA, with no loss of function of either molecule. We believe that, by 
rationally choosing adjuvant-mRNA combinations, this modular platform can help 
standardize vaccine studies and allow for specific and directed immune responses in 




Preparation of IVT mRNA 
To synthesize IVT mRNA encoding for cytoplasmic ovalbumin, a DNA template was 
prepared from the PCL-neo-cOVA plasmid from Addgene (Plasmid #25097).  The Kozak 
consensus sequence and 3' UTR from murine alpha globin was modified with overlap 
extension PCR and was verified with Sanger sequencing (MWG Eurofins). The DNA 
template was amplified using the Q5 high-fidelity DNA polymerase (New England Biolabs), 
purified using the QIAquick PCR purification kit (QIAGEN), digested with the restriction 
enzyme NOTI to create a 5' overhang, and then purified again. The T7 mScript Standard 
mRNA Production System was used to generate IVT mRNA (Cellscript), add a Cap-1 
structure, and a poly(A) tail. Manufacturer's instructions were followed; the RNeasy mini 
kit (QIAGEN) was used to purify IVT mRNA when necessary. To incorporate modified 
bases, pseudouridine-5'-Triphosphate, 5-Methylcytidine-5'-Triphosphate, and N1-
Methylpseudouridine-5'-Triphosphate (TriLink Biotechnologies and USB) were replaced in 
the 25mM ribonucleotide cocktails. Cytosine triphosphate was purchased from Affymetrix. 
IVT mRNA was treated with Antarctic Phosphatase (New England Biolabs) for 30 min to 
remove residual 5′-triphosphates, and then purified with the RNeasy kit, quantified using 
the Nanodrop 2000 (Thermo Scientific), and then stored at -80ºC.  
 
Preparation of Neutravidin-labeled targeting oligonucleotides 
Figure 2 describes the overall schematic procedure for tethering small molecule agonists 
to IVT mRNA.  2'O-Methyl RNA/DNA chimeric oligonucleotides were purchased from 
Biosearch Technologies with the following sequences, which are complementary to the 3’ 
UTR of the IVT mRNA:   
5’-TTTTTTTGCAAGCCCCGCAGAAGG-3, 5’-TTTATTTAGAGAAGAAGGGCAUGG -3’, 
5’-TTTTTTACCAAGAGGUACAGGUGC-3’, 5’-TTTTTTTCUACUCAGGCUUUAUUC-
3’where the boldface indicates 2’-O-Methyl RNA.  Each oligonucleotide contained a 
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disulfide C6 5' modification, which was used for conjugation to Neutravidin using Solulink 
chemistry.  The 5’ disulfide was reduced by incubation with tris(2-carboxyethyl)phosphine 
(TCEP) (5mM) (Thermo Fisher Scientific). Oligonucleotides were then filtered (3kDa 
MWCO, Millipore) to remove the reducing agent. Oligonucleotides were then modified with 
a HyNic functional group by overnight incubation with 20 µg Maleimide HyNic (Solulink) 
and 0.3 mM ethylenediaminetetraacetic acid (EDTA) (Sigma). The modified 
oligonucleotides were individually buffer exchanged into conjugation buffer with centrifugal 
filtration (3kDA MWCO). Separately, Neutravidin (500 µg) was labeled with succinimidyl-
4-formylbenzamide (S4-FB, 20 µg) (Solulink) in Solulink’s modification buffer for 2 hours 
at room temperature. Neutravidin was then buffer exchanged into Solulink’s conjugation 
buffer with centrifugal filtration (30kDA MWCO, Millipore). To conjugate Neutravidin to the 
oligonucleotide, the reagents were incubated for two hours at room temperature at a 1:2 
molar ratio in the presence of 1x Turbolink catalyst (Solulink).  Unconjugated 
oligonucleotides were removed by centrifugal filtration (30kDA MWCO). The final 
neutravidin concentration was determined by bicinchoninic acid assay (Pierce) against a 
standard curve. The nucleic acid concentration was determined by measuring the 
absorbance at 260 nm using the Nanodrop 2000 (Thermo Scientific). The reaction was 
optimized to yield approximately a 1:1 molar ratio of Neutravidin:oligonucleotide for each 
mRNA targeting sequence. The resulting probes were stored at 4ºC.  
 
Preparation of agonist-tethered IVT mRNA 
Biotinylated adjuvants (Pam2CSK4 biotin, and CL264 biotin) were purchased from 
Invivogen and were incubated with oligo-conjugated Neutravidin at room temperature for 
1 hour in PBS at a 5:1 molar ratio. The resulting mMTRIPS were purified from unbound 
agonists by centrifugal filtration (30 kDA MWCO, Millipore).   
23 
 
To anneal the adjuvants to IVT mRNA, the latter was first incubated at 75ºC for 5 minutes 
to remove secondary structures and immediately placed on ice. Each mMTRIP was then 
added to the solution and incubated with IVT mRNA at a 1:1 molar ratio for approximately 
12 hours at 37ºC for hybridization. Unbound targeting oligonucleotides were removed by 
filtration (200 kDA filter, Advantec) and then concentrated using a 30 kDa centrifugal filter. 
The nucleic acid content was quantified by measuring the absorbance at 260 nm. To 
confirm removal of unbound adjuvant, a mock reaction without IVT mRNA was prepared 
as described. The number of adjuvants bound to IVT mRNA was estimated using 
biotinylated Atto 565 dyes. Conjugation was performed as described. Following 
purification, the dye fluorescence and RNA 260nm absorbance were measured.  IVT 
mRNA fluorescence was compared to a standard curve of Atto 565 dye to determine IVT 
mRNA degree of labeling.  
 
Cell line and transfection 
The RAW264.7 mouse macrophage cell line (ATCC TIB-71) was maintained in High 
Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza) with 10% FBS (Hyclone) 
and 100 U/ml penicillin and streptomycin (Invitrogen). Approximately 60,000 cells were 
seeded in a 24 well plate the evening prior to transfection with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol.  
 
Proximity ligation assay to measure TLR7 activation  
Cells were transfected with 250 ng of modified RNA or 500 ng of unmodified mRNA either 
unlabeled or labeled with MTRIPS. At the indicated time points, cells were fixed with 1% 
paraformaldehyde in PBS for 10 minutes, permeabilized with 0.2% Triton X100 in PBS for 
5 minutes, and TLR7 -IRAK4 interactions were quantified by a proximity ligation assay 
according to manufacturer’s instructions (Sigma Aldrich). Primary antibodies utilized were 
rabbit anti-TLR7 (Novus, cat# NBP2-24906), and mouse anti-IRAK4 (LS Bio, cat# LS 
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BIO452). Images were acquired using an UltraVIEW spinning disk Zeiss LSM 510 Meta 
confocal microscope with a Hamamatsu Flash 4.0v2 CMOS camera and a 63×, NA 1.4 
Zeiss Plan-Apochromat oil objective. Imaging was controlled by the Volocity acquisition 
software (PerkinElmer). Image stacks were recorded at 350 nm intervals. PLA punctae 
were counted using the Volocity analysis software, which identified punctae over a signal 
intensity threshold. The number of punctae per cell was counted for each condition (thirty 
to forty cells per sample).  
 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) on cell 
culture samples 
Six hours following cell transfection, total RNA was collected with the RNeasy mini kit 
according to manufacturer’s protocols, including homogenization using the QIAshredder 
and an on-column DNAse treatment. RNA content was quantified by absorbance at 260 
nm and 1 ug of RNA was retro-transcribed to cDNA using the RT2 First Strand kit (SA 
Biosciences). qRT-PCR was performed in triplicates using the StepOnePlus real-time 
PCR system (Applied Biosciences) with 15 ng of cDNA and SYBR green master mix (SA 
Biosciences), according to manufacturer's instructions. Gene-specific primers for ACTB 
(as a reference gene), IFNβ-1, and IL-1β and IL-6 were designed by and purchased from 
Fluidigm. Fold changes and 95% confidence intervals were calculated using the ddCT 
method on the StepOne software in reference to beta-actin. Significant differences were 
determined by an ANOVA test followed by Tukey-Kramer's post analysis. Each 
experiment was independently repeated at least two times. 
 
Flow cytometry analysis of protein expression 
Cells were transfected with IVT mRNA as described. Cultured cells were resuspended 
using Versene solution (Thermo Fisher Scientific), washed in PBS + 2% FBS, fixed with 
4% paraformaldehyde for 10 minutes, washed two times with PBS + 2% FBS, and then 
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permeabilized with 0.2% triton X-100 in PBS. Cells were then stained for transgene 
expression using an anti-ovalbumin FITC antibody (Abcam) diluted 1:50 in PBS with 2% 
FBS and 0.1% triton X-100 for 30 minutes at 4°C.  Cells were washed twice with PBS + 
2% FBS and 0.1% triton X-100 and then analyzed using an BD Accuri C6 Cytometer. 
Samples were gated to remove debris, doublets and to demarcate the ovalbumin+ 
population for determination of median fluorescence.   
 
Murine intramuscular injections 
Female BALB/c mice (Charles River, Wilmington, MA) were anesthetized with 2.5% 
isoflurane and then injected in the anterior tibialis with 40 µl of indicated treatment (10 µg 
of IVT mRNA and/or 0.314 nmol CL264 diluted in RiLa) using a 29-gauge needle. Five 
mice were immunized per condition. For adaptive immunity experiments, mice received 
the vaccine once on day 0 and once on day 23. Mice were euthanized on day 41, blood 
was collected by cardiac puncture for anti-ovalbumin analysis and spleens were harvested 
for ELIPSOT analysis. Mice were housed and manipulated under specific-pathogen-free 
conditions in the animal care facilities of Georgia Institute of Technology. All experiments 
were conducted in accordance with the Institutional Animal Care and Use Committee.  
 
RT-qPCR on mouse muscle tissue 
Five hours following intramuscular injection, the muscle was removed and stored in 
RNAlater (Thermo Fisher Scientific) overnight at 4ºC. The following day, tissue was 
homogenized using the Bullet Blender and Navy RNAse free stainless-steel beads (Next 
Advance) in the presence of 1 ml of Trizol (Thermo Fisher Scientific).  Samples were 
extracted with chloroform, mixed with an equivalent volume of ethanol, and then purified 
according to the RNEasy kit's instructions, which included an on-column DNAse digestion. 
RNA content was determined by A260 absorbance using the Nanodrop 2000, (Thermo 
Fisher) and quality was checked by RNA gel electrophoresis. Extracted RNA (1 µg) was 
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reverse-transcribed to cDNA using the RT2 PreAMP pathway primer mix (QIAGEN) 
according to the manufacturer's directions. qPCR was conducted using the Fluidigm 
system and the mouse antiviral response PCR primer array (QIAGEN) according to the 
manufacturer's directions with technical duplicates. Five mice were analyzed per 
treatment condition. QIAGEN’s online data analysis center was used for data analysis. 
Statistical significance was based on a Student’s t-test of the replicate 2-ΔCT values for 
each gene in the control group and treatment groups. The reference genes Gusb, Gapdh, 
Hsp90ab1, and ActB were used to normalize expression. Heat maps for gene expression 
were generated in JMP using the multivariate clustering tool.   
 
Enzyme linked immunospot (ELISPOT) assays 
Mouse IFN-γ and IL-4 ELISPOT assays were conducted according to the manufacturer’s 
instructions (BD Biosciences). Spleens were removed from the mice and a spleen 
dissociator kit (Miltenyi) was used to assist harvesting. Splenocytes were treated with red 
blood cell lysis buffer, washed in PBS, and then resuspended in RPMI (Gibco) 
supplemented with 10% FBS (Hyclone) and 100U/ml penicillin/streptomycin (Invitrogen). 
Cell viability and concentration was assessed with trypan blue. Cells were plated in 
triplicate in 96 well ELISPOT plates at 106 cells/ml. Cells were stimulated with either whole 
ovalbumin protein (for IFN-γ and IL-4 assays) or the SIINFEKL peptide (for IFN-γ assay) 
overnight (2 mmole/ml). Each assay included a non-stimulated cell negative control as 
well as stimulation with a PMA/Ionomycin cocktail positive control. Following cytokine 
staining, plates were imaged with the CTL S6 Core Analyzer ELISPOT plate reader 
(Immunospot).  
Cell spots were counted using the image analysis software Volicity. To quantify cellular 
cytokine spots, images were background subtracted then thresholded based on the 
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intensity of the spots observed in the control wells. With this highpass filter applied, the 
number of cell spots were then counted in each well.  
 
Enzyme-linked immunosorbent (ELISA) assay 
Mouse serum was collected on day 41, and assessed for total anti-ovalbumin IgG using a 
mouse ovalbumin IgG ELISA kit (MyBioSource). Serum samples were diluted 1:100 in the 
sample diluent supplied, and processed according to the manufacturer’s protocol. The 
mouse monoclonal 6C8 anti-ovalbumin antibody (Abcam) was diluted in serial 2-fold 
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Understanding the spatiotemporal trafficking of vaccines after delivery can aid in their 
rational design during preclinical and translational studies. Here we demonstrate a dual 
radionuclide:near-IR platform to non-invasively monitor non-human primate mRNA 
vaccine trafficking in a longitudinal, quantitative manner via PET/CT, while preserving the 
ability to investigate events at the tissue and single cell level. This approach is modular 
and flexible because the RNA is directly labeled, allowing any vaccine formulation to be 
utilized, without impeding antigen expression or inducing additional immune responses. 
We show that at 4 hours post-IM administration, mRNA was present in 3 draining lymph 
nodes; after 24-hours, the signal increased in the draining lymph nodes by an average of 
70%, while it decreased at the injection site by 40%. Cellular analysis of tissues 28 hours 
post-injection demonstrated that dendritic cells (DCs) and B cells were the primary cells 
containing the injected mRNA and encoded protein. Due to its non-invasive nature, we 
believe this approach will reveal critical spatiotemporal determinants of vaccine efficacy in 









Figure 2.1: Experimental workflow and outline after intramuscular injection of 
64Cu:DyLight 680 labeled YF prME mRNA. Whole body PET/CT imaging was 
performed at 4 hours and 28 hours. Two animals were sacrificed at 28 hours and mRNA 
positive tissues identified and extracted utilizing a portable near-IR camera. The extracted 
tissues were then examined at the cellular level with microscopy and flow cytometry. 







Non-invasive approaches to longitudinally monitor vaccine responses and efficacy in a 
reliable manner are urgently lacking. Current vaccine efficacy prediction metrics (known 
as correlates of protection) are often dependent on host-responses that take months to 
develop55, and are invasive in nature. The requisite gap between administration and 
evaluation56 may result in potential infection with the pathogen of concern before vaccine 




Synthetic messenger RNA (mRNA) has garnered considerable interest as a biotechnology 
platform. The short-lived nature of mRNA provides an inherent safety advantage over DNA 
based approaches as the transcripts are unlikely to enter the nuclear compartment and 
cannot integrate into genomic DNA. Critically, mRNA-based vaccines are particularly 
attractive due to their simplicity of design and production, allowing the medical community 
to respond quickly and at scale to mutating and emerging pathogens. They are also highly 
amenable to personalized therapy, such as for various cancers57.  
 
In the context of RNA vaccine development, a balance between expression of the epitopes 
that host immunity needs to target, and immune stimulation, is required to develop 
adaptive immunity and protection54. Efficacious mRNA vaccines often contain adjuvants 
that are used in tandem with mRNA to stimulate directed innate responses that drive 
appropriate adaptive immunity20,22. Delivery vehicles such as lipid nanoparticles (LNPs), 
in addition to protecting mRNA from nucleases, can also be considered adjuvants, as they 
are not immunologically inert and demonstrate innate stimulating properties independent 
of the complexed mRNA58,59. The use of adjuvants with mRNA to elicit protection has been 
demonstrated in animal models of Flu60, Zika61, and cancer57, among others. To date 
however, no mRNA-based vaccine has successfully demonstrated protection in a phase 
3 clinical trial57.  
 
It is apparent that a vaccine or therapeutic agent can only be effective if it localizes to 
relevant tissues that require the intervention. After intramuscular or intradermal 
administration of mRNA, dendritic cells (DCs), which when activated migrate to draining 
lymph nodes, have a strong proclivity for mRNA uptake62, whether naked63 or 
encapsulated in LNPs20,64. The complex immune milieu that ultimately develops requires 
expression and presentation of antigen to lymph node based B and T cells for robust 
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humoral and cell mediated adaptive immunity to develop65.   Multiple delivery routes (IP, 
IV, IM, ID) are typically evaluated for a given adjuvant/delivery vehicle formulation, based 
on their ability to generate differential correlates of protection66,67 . Additionally, due to 
safety concerns, off-target delivery to unintended organs should be thoroughly 
investigated. 
 
During vaccine development, an assumption is often made that the delivery distributions 
observed in lower animal models reliably translate to humans. New non-invasive 
strategies that allow precise monitoring of mRNA after delivery in large mammals (i.e. non-
human primates and humans) would prove a useful tool to rapidly screen, evaluate, and 
compare potential vaccine formulations. For clinical investigations, no such systemic and 
non-invasive methodology currently exists. In pre-clinical studies, tissue light scattering 
impedes the utility of commonly deployed optical imaging methodologies, such as 
luminescence and fluorescence, in larger animal models. Invasive molecular tagging 
techniques, such as barcoding, are useful tools to investigate drug distribution, but they 
would be even more powerful if used in combination with an unbiased systemic imaging 
approach. 
 
Here, we demonstrate the use of PET/CT imaging as a non-invasive means to monitor, in 
a quantitative manner, the trafficking of a model mRNA vaccine to draining lymph nodes 
in cynomolgus macaques.   We chose yellow fever (YF) prME mRNA as a model system, 
as the live attenuated 17D virus vaccine provides robust and widespread protection, and 
as such represents a gold standard to evaluate and compare experimental vaccines. We 
directly labeled the mRNA with an orthogonal dual PET:near-IR probe, an approach 
agnostic to formulation, carrier, or route of delivery. The mRNA was complexed with lipid 
derivatives of natural amino sugars used to deliver RNA structures68–70 and delivered via 
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intramuscular injection (IM), the most common route of delivery for vaccines in humans. 
By choosing 64Cu, a radioisotope with a half-life of 12.7 hours, we reasoned that any 
vaccine formulation could be precisely tracked for days following administration.  
 
PET/CT was used to monitor the first 28 hours of mRNA trafficking dynamics with high 
spatiotemporal resolution (Fig. 2.1). Substantial signal in draining lymph nodes was 
observed in three anatomical regions at 4 hours post-injection and it increased over the 
next 24 hours by an average of 70%. Subsequently, near-IR fluorescence allowed us to 
confirm the systemic level events indicated by PET imaging and to investigate mRNA 
localization within tissues and the cell types involved with vaccine trafficking at the 
injection site and in the draining lymphoid organs. We believe this study establishes PET 
imaging as a viable platform to monitor and characterize delivery of mRNA therapeutics 
and vaccines in large-mammals, and, as such, has potential implications for pre-clinical 















64Cu:DyLight 680 Labeling of YF prME mRNA  and IM Injection 
 
We previously demonstrated orthogonal fluorescent labeling of IVT mRNA through the 
use of tetravalent NeutrAvidin:oligo nucleotide complexes (MTRIPS) targeting the 
3’UTR49,71,72, achieving sufficient signal-to-noise ratios without comprising translational 
capacity or stimulating immune responses. Here, in addition to labeling the oligos 
fluorescently, we conjugated the divalent cationic chelator DOTA to the NeutrAvidin 
protein core (Fig. 2.2a). The resulting probes contained two components: a) DyLight 680 
labeled oligos complementary to the 3’UTR of the mRNA for near-IR imaging and b) 




Figure 2.2: Approach to orthogonally label YF prME mRNA with dual 
radionuclide:near-IR probes. (A) Schematic demonstrating mRNA labeling with 
radioactive:near-IR probes. (B) immunofluorescence (IF) analysis of protein expression in 
HeLa cells after Lipofectamine 2000 transfection with YF prME-encoding mRNA. Green 
represents staining for the YF prME protein, while red designates the fluorescently labeled 
prME mRNA. (C) Quantification of IF analyses, demonstrating efficient translation of a 
DOTA:DyLight 680 labeled YF prME mRNA and the corresponding unlabeled mRNA. (D) 
qPCR analysis of gene expression demonstrates no differential activation of innate 
immune response genes (IL1b, IL6, and IFNb1) between labeled and unlabeled mRNA in 






The probes were labeled with the radionuclide PET reporter 64Cu and annealed to the 
mRNA 3’UTR at a molar ratio of 1:0.5 of mRNA to probe, as optimized through size 
exclusion HPLC (data not shown). Efficient protein expression and negligible innate 
immune activation were confirmed via in vitro transfection (Fig. 2.2 b-d), with respect to 
non-labeled mRNA. Before injection, the 64Cu:DyLight680 labeled YF prME mRNA was 
complexed with the aminoglycoside lipidic derivative CholK containing a kanamycin polar 
head group and a cholesterol moiety as a hydrophobic portion. We have previously 
demonstrated that mRNA complexed with CholK, at low mRNA to nanoparticle charge 
ratios (0.1), entered via clathrin mediated endocytosis, was released from the endosome, 
and protein was expressed efficiently in vivo49. Four cynomolgus monkeys (6kg-8kg) were 
injected with 200ug (0.8mCi in a total volume of 500uL of Ringers lactate) of CholK 
formulated YF prME mRNA in the right quadriceps. Animals were imaged via whole body 
PET/CT at 4 hours and 28 hours post-injection, in a clinical grade scanner.  
 
PET/CT reveals a consistent spatial distribution of IVT-mRNA 
 
PET/CT images of AFO32 at 4 hours post-immunization are used to illustrate the general 
results observed at the a) injection site and b) draining lymph nodes (Fig. 2.3a). mRNA 
was clearly visible at the site of injection in the right quadriceps, as well as in three draining 
lymph node regions: inguinal, iliac, and paraaortic. The signal magnitude in a given LN 
decreased with Euclidian distance from the injection site (Fig. 2.3b). The distance between 
the injection site and the most distal paraaortic LN was 9.2cm. This observation, combined 
with known draining patterns, indicates that the order of trafficking from the injection site 




Figure 2.3: Representative PET/CT images of non-human primates 4 hours after 
64Cu IM vaccine delivery. (A) Whole body coronal and sagittal PET/CT images for 
animal AF032, four hours after delivery. The injection site in the quadriceps and 3 lymph 
node clusters - Inguinal, Iliac, and paraarotic – display standard uptake value (SUV) levels 
above background. All sections are contrasted equally. (B) An expanded view of the inlet 
of (A) demonstrates a maximum Euclidian distance between injection site and the most 
distal node (paraaortic) of 9.2 cm. (C) Individual draining lymph nodes within an 
anatomical lymph node chain are distinguishable using appropriate contrast 
enhancement.  
 
The exact number and connections between LNs within an anatomical chain varies per 
animal. As a result, if signal contrast is appropriately enhanced, numerous LNs within an 
anatomical region can be resolved: AFO32, for instance, displayed two draining iliac LNs 
(Fig. 2.3c). For purposes of quantification and comparison, these individual LNs were 
grouped by anatomical regions into single entities in subsequent analyses (i.e. the two-
draining iliac LNs of AFO32 are reported as a single iliac LN).  
 
These consistent trafficking patterns were confirmed at 28 hours post immunization. 
Figure 2.4 shows the four relevant anatomical regions of each animal, presented from 





Figure 2.4: PET/CT images of non-human primates 28 hours after 64Cu IM vaccine 
delivery. PET/CT fusion images of each animal at 28 hours post injection, for all 4 
anatomical regions with SUV signal above background. All images are contrasted equally, 
according to the scale bar. Magenta arrow heads indicate the organ specified by the 
column header. A red square inscribes the organ of interest in cases when the signal is 




Longitudinal PET/CT monitoring of mRNA trafficking 
 
The mRNA distribution over time was assessed by measuring changes in the PET signal 
over time, as highlighted through heat map profiling of the maximum standard uptake 
value (SUV) (radioactivity normalized to dose and body weight) intensity at the injection 
site and Iliac LN at 4h and 28h, after equal contrast enhancement (Fig. 2.5a). For each 
anatomical area, a region of interest (ROI) was circumscribed based on high-pass 
thresholding above the lowest 28% of signal. The integrated SUV values across these 
ROIs were reported for each organ (Fig. 2.5b). The total signal at the injection site was an 
order of magnitude higher than in any draining LNs for all time points. In general, the total 
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SUV of a given LN was inversely correlated with its Euclidian distance from the injection 




Figure 2.5: Total SUV increases over 24 hours in draining lymph nodes  
(A) Visual representation of the SUV signal changes observed from 4 hours to 28 hours 
in AFO32. The SUVmax decreased at the injection site over time, and increased in a 
draining iliac LN. (B) Integration of SUV signal in each animal based on each anatomical 
region at 4 and 24 hours. Note that while absolute values vary across regions, signal 
generally increased in LNs and decreased at the injection site. (C) Fold change in Total 
SUV over 24 hours. Horizontal lines designate the median, with error bars representing 
the 95% CI.  
 
 
The signal changes over time for each organ were statistically significant (p < 0.05). The 
average decrease in total SUV was 45% in the muscle at the injection site. The draining 
LNs showed an average increase of 1.5x in the inguinal, 1.9x in the Iliac, and 1.4x in the 
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paraaortic (Fig. 2.5c). To achieve accurate comparisons across time, background levels 
in the contralateral muscle were used to normalize absolute SUV and account for any 
instrument parameter differences during image acquisition. 
 
Of note, the Iliac LN of AF031 was distinct from the other LNs, with detectable, yet 
extremely low total SUV values. Nevertheless, the sensitivity and high dynamic range of 
PET imaging allowed for quantification over time. This result is perhaps, in part, due to the 
intramuscular injection for this animal being markedly medial and peripheral compared to 
other injection sites (Figure 4). As such, the iliac LN of AF031 was used to estimate the 
sensitivity of PET/CT imaging to be 15.4 ng of mRNA per cm3 (see methods for 
calculations). 
 
In conclusion, in vivo imaging of the radiolabeled mRNA by PET/CT demonstrated that 
upon IM injection, mRNA reaches draining lymph nodes relatively quickly and continues 
to accumulate for at least 28 hours after injection. We next sought to examine mRNA 
distribution and protein expression at the tissue and cellular level, to characterize the cell 
types involved with mRNA trafficking.  
 




Two animals were euthanized 28 hours post injection and experimentally relevant tissues 
were selectively extracted during necropsy with the help of a portable near-IR camera. We 
observed that, in general, for each anatomical region, a single node of a chain was positive 
for mRNA signal while the other nodes were negative. Interestingly, a dissected inguinal 
node contained only a well-demarcated portion of its volume positive for mRNA signal 
(Fig. 2.6a). This result highlights the utility of a reporter system to specifically identify 
immunologically relevant tissues, as the signal-to-noise ratio in downstream analyses - 
such as qPCR, IHC, flow cytometry – may be negatively affected without such screening. 
Portions of the tissues (positive and negative) were cryopreserved as whole tissues or 
dissociated cells, for IHC and flow cytometric analyses, respectively.  
 
Figure 2.6: Near-IR assisted tissue extraction demonstrates robust mRNA transport 
and prME protein expression in muscle and ipsilateral lymph nodes. (A) At the time 
of necropsy, a portable near- infrared imager was used to identify mRNA positive tissues. 
The arrow represents a positive LN, while arrowheads point to nearby negative lymph 
nodes. An excised Iliac LN displayed distinct compartmentalization, with only a minor 
portion containing mRNA. Contralateral organs were processed in parallel as negative 
controls. All laser power and exposure times were empirically determined by minimizing 
background on negative controls. (B) A whole organ stitch of an ipsilateral LN from AF032 
at 20x magnification. mRNA (blue) appears in central regions of the node, while expressed 
protein (red) predominately, but not exclusively, is located on the external capsule of the 
LN. The section was also stained for CD20 (green). (C) Ipsilateral muscle stitch at 40X 
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magnification demonstrating mRNA and protein distribution in blue and red, respectively; 
the DAPI signal was purposely contrast enhanced to visualize muscle fibers.  
 
Immunofluorescence staining revealed the spatial distribution of both administered mRNA 
and expressed prME protein within the extracted organs (Fig. 2.6 b-c and Fig. 2.7). YF 
prME protein expression in the lymph node was confirmed by staining tissue sections 
using two different polyclonal antibodies (Fig. 2.8).  
 
Stitched cross-sectional images of iliac LN (Fig. 2.6b) and skeletal muscle (Fig. 2.6c) 
indicated that, as expected, mRNA retained its translational capacity, as evidenced by 
protein staining within both tissues. In the iliac LN, prME antigen was mainly concentrated 
in the region of the subcapsular sinus, while the mRNA was distributed immediately 
outside the trabecular sinuses, near the periphery of the well demarcated germinal centers 
(Fig. 2.6b: crop). It is important to note that YF prME is secreted by cells upon translation. 
Thus, the large amount of antigen detected on the external edges of the LN could be 




Figure 2.7:  Stitches for macaques iliac LN and muscle from uninjected shams. (A) 
Stitch of sham Iliac LN stained for YF protein (red), cell type marker CD20 (green).  Images 
were taken on an Elyra confocal microscope with 20X objective. Scale bar is 200 µm. (B) 
Stitch of sham muscle stained for YF protein (red), cell type marker CD11b (green). 
Images were taken on an Elyra confocal microscope with 40X objective. Scale bar is 100 






Figure 2.8: Yellow fever prME protein expression with two different antibodies in 
macaque iliac lymph node. Lymph node tissue stained for YF prME protein with YF 
antibody raised in mouse (blue) and rabbit (green). mRNA is in red and DAPI in white. 






APCs are the primary cell type that express synthetic mRNA 
 
First, we aimed to confirm that mRNA co-localized with prME antigen. Line profile analyses 
on lymph node tissue sections indicated that mRNA fluorescence signal spatially 
overlapped and correlated with prME antigen staining (Fig. 2.9a and Fig. 2.10). Next, we 
characterized the cell populations that contained the mRNA and expressed antigen via 
immunofluorescence co-localization analyses. Tissues were stained with the following 
immune cell markers: CD86 (APCs), CD20 (B cells), CD11c and CD123 (Myeloid and 
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Plasmacytoid DCs, respectively), CD4 (predominately T cells, but also DCs) and CD68 
(Macrophages). Specific immune cell markers were utilized to measure the fraction of 
mRNA positive cells or protein positive cells in each tissue section that were positive for a 
specific immune cell marker (Suppl. Fig. 2.11-2.13). (i.e. we selected for mRNA positive 
cells, then examined the fraction of these positive cells that co-stained with the immune 
cell marker stained for in that slide).   
 
The majority of mRNA was found in CD123+ (70%) and CD20+ (20%) cells, specific 
markers for plasmacytoid dendritic cells and B cells, respectively (Fig. 2.10b). The 
inducible APC marker CD86 was present in 85% of mRNA positive cells. For the prME 
antigen, a remarkably similar cell subtype distribution was observed (Fig. 2.10c). mRNA 
and protein expression were also observed, to a lesser degree, in B cells, perhaps 





Figure 2.9: APCs are the primary cell type containing mRNA and protein in muscle 
and LN. (A) Line profile co-localization analysis in LNs was used to confirm spatial 
correlation between prME antigen (green) and mRNA (red). LN cells with mRNA (B) or 
protein (C) were phenotyped based on cell surface markers. Plotted values are the 
proportion of mRNA/protein positive cells containing the immune cell marker indicated. 
IHC analysis was used to quantify the proportions, with a minimum n >= 40. In muscle 
tissue, the fraction of mRNA+ cells based on cell type (D) and immune cell sub-types out 




A similar cell phenotype analysis was performed for muscle tissue. mRNA positive cells 
were selected and their phenotype determined via line profile co-localization analyses 
(Fig. 2.10d). We stained for specific cell markers, including dendritic cells (CD123 and 
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CD11c), B cells (CD20), macrophages and monocytes (Cd11b), APCs (CD86) and T cells 
(CD4). The predominant population of infiltrating immune cells recruited to the muscle 
consisted of antigen presenting cells and dendritic cells (Figure 2.10d). However, it proved 
difficult to identify sufficient prME antigen containing cells on a given tissue section for 
meaningful statistics. Thus, in lieu of antigen analyses, we characterized the infiltrating 
immune cell population at the injection site. Approximately 50% of immune cells in muscle 
were APCs (Fig. 2.10e). We did not observe infiltrating B cells in muscle tissue (data not 
shown). Flow cytometric analysis of lymphocyte activation suggests increased numbers 
of cells with activation makers CD25 and CD69 in the draining ipsilateral iliac LN, but not 
in the contralateral iliac LN (Figure 2.14). Further, these cells proved to be Fas receptor 
(CD95) positive CD4+ T cells. The CD25+ cells were also Foxp3-/CD127-, indicating that 







Figure 2.10: Yellow fever prME mRNA and protein expression in immune cells of 
Iliac lymph node of Macaques.  Lymph node tissue sections from sham and monkey 
injected with 200ug of dylight 680 labeled mRNA (red) complexed with Cholk at charge 
ratio 0.1 in monkey muscle intramuscularly. Tissue sections were stained with immune 
cell marker (blue) CD20 (A) and CD86 (B), YF prME protein (green) and counterstained 
for DAPI (white). Sham from uninjected monkeys and isotype control are shown. Images 
were taken on an Elyra confocal microscope with 40Xobjective. Scale bars are 30 µm. 







Figure 2.11:  Stitches for macaques iliac LN. Stitches of Iliac LN stained for YF protein 
and cell type marker CD11c (A), CD123 (B), CD4 (C) and CD86 (D). mRNA is shown in 
blue, protein in red, cell type marker in green and DAPI in white. Images were taken on 










Figure 2.12: Infiltrating immune cells (APCs, Macrophages) and YF prME protein at 
site of injection. Cynomolgus macaque muscle injected with labeled mRNA and 
contralateral tissue stained with protein in green, immune cell marker in blue [Cd86 (A) 
and Cd11b (B)], mRNA in red and DAPI in white. Images were taken on an Elyra confocal 




Figure 2.13: Infiltrating immune cells (Dcs, T cells) and YF prME protein in muscle 
tissue of macaques. Cynomolgus macaque muscle tissue and contralateral stained with 
protein in green and immune cell marker in blue [CD11c (A) and CD4 (B)], mRNA in red 
and DAPI in white. Images were taken on an Elyra confocal microscope with 40Xobjective. 











Figure 2.14: Activation of CD4+ T cells in the draining ipsilateral LN. Contralateral 
iliac LN lymphocytes display an upregulation of early activation markers CD25 and CD69, 
as well as Fas Receptor CD95, as compared to contralateral (ie non-draining) iliac lymph 
node primary cells from the same monkey. Further gating of CD25+CD95+ double positive 







Current non-invasive whole-body imaging technologies (i.e. luminescence) are less 
applicable to large mammals, due to size constraints as well as being optically thick. 
PET/CT data demonstrate a quantitative, tomographic, and sensitive method to follow 
mRNA trafficking upon delivery in an in vivo setting longitudinally in non-human primates. 
The estimated fundamental resolution limit for clinical and pre-clinical PET scanners is 
1.83 mm and 0.67mm, respectively73. Based on our experimental data, we estimate the 
sensitivity to be 15.4 ng of mRNA per cm3. At 4 hours post-IM administration, mRNA was 
present in 3 draining lymph node anatomical regions. Over a 24-hour period, the signal 
increased in the draining lymph nodes by an average of 70%, while mRNA in the muscle 
injection site decreased by 40%. Cellular analysis of near-IR positive tissues 28 hours 
post-injection demonstrated translation of encoded protein and that dendritic cells (DCs) 
and B cells were the primary cells containing the injected mRNA and encoded protein. 
Critically, the four monkeys in this study displayed remarkably consistent trafficking 
patterns, hinting at the robust nature of this tracking technology. Based on this sensitivity 
and 64Cu half-life of 12.7 hours, it is reasonable to expect signal above background for at 
least 4 days (or 7.6 half-lives) post administration. Additionally, PET scanners are a staple 
of most hospitals, and as such as a resource are relatively available for translational 
studies.  
 
During necropsy, near-IR signal from the dual-labeled probes was used to extract only 
relevant portions of organs that contained the RNA of interest, or at the least the single 
positive node of a lymphatic chain of nodes. We believe using such a positive screening 
approach is critical to achieve high signal-to-noise and to mitigate sampling errors, 
particularly in the case where low frequency cell types are being investigated (ie antigen 
specific CD8 cells and DCs). Whole LN stitched images at 28 hours post IM injection 
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indicated that the mRNA was spatially located just outside the B cell follicles, while YF 
prME antigen was observed in the interior of the germinal centers. Moreover, we observed 
upregulation of T cell activation markers in the lymph nodes, suggesting signaling changes 
in the LN microenvironment.  
 
The proposed imaging platform is inherently flexible and modular, in regard to both the 
protein that is encoded by the mRNA and the carrier that encapsulates the RNA cargo. 
Labeling the mRNA directly (i.e. before encapsulation) allows this technique to be used 
with any carrier or delivery system. In this study, the nanoparticle CholK was selected as 
aminoglycosides are natural compounds known to interact specifically with RNA 
structures, but any nanoparticle could be utilized in practice. Furthermore, the technical 
hurdle to label DNA in an analogous manner is minimal. This allows for head-to-head 
comparisons between vaccine formulations of interest to be conducted.  
 
Still an open question is the degree to which muscle protein expression is a determining 
factor in subsequent antigen specific immune responses. Producing an innate immune 
response in the muscle is beneficial due to potent chemokine and cytokine production that 
recruits immune cells74,75, but it is possible that the primary consequence of this in terms 
of vaccine efficacy is increased antigen transport to lymph nodes, where antigen 
presentation to T helper cells and costimulatory molecule activation occurs76–78. In this 
study, we observed prME expression in the muscle and general recruitment of APC 
immune cells to the injection site. In the LNs, plasmacytoid DCs were the primary cell 
types containing mRNA and expressing prME protein.  
 
The transport of vaccine components to secondary lymphoid tissue can occur in a passive 
manner that is driven by convective forces or in an active, cell mediated manner by antigen 
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presenting cells that infiltrate the tissue due to cytokine and chemokine signaling gradients 
brought about by inflammation76. Passive convection occurs in minutes to hours after 
delivery, while active transport is on the order of hours to days. These two modes of 
antigen delivery to lymphoid tissue are not equivalent however, and there is evidence that 
antigen presentation without cellular activation contributes to tolerance76. While we are not 
able to resolve using this approach which transport mechanisms are primarily responsible, 
the strong draining LN signal we observed at 3.5 hours suggests that imaging within 30-
60 minutes after injection could help delineate the transport mechanism.  
 
A barrier slowing down effective vaccine development is the empirical manner by which 
vaccines are evaluated, in a trial and error fashion, without a detailed understanding of 
the reasons they worked in the first place54 . The parameters of a given vaccine, including 
adjuvant, delivery vehicle, and route of administration each have profound impacts upon 
the type of immune response generated and subsequent vaccine efficacy21. With each 
vaccination approach having its advantages and disadvantages based on the treatment 
setting, understanding and reverse engineering the spatiotemporal kinetics of successful 
vaccines could allow for the rationale development of vaccines that share similar trafficking 
characteristics. In other words, knowing the ‘why’ and ‘how’ of a successful vaccine can 
aid in improving the efficacy of other, less efficacious vaccines.  
 
Although beyond the scope of this study, linking acute vaccine trafficking events with 
downstream adaptive immune responses has the potential to shed light on critical 
spatiotemporal determinants of vaccine efficacy. The early sequelae following injection of 
vaccine formulations determine the nature and magnitude of downstream adaptive 
immune responses4,79,80. This information could be used to correlate vaccine efficacy with 
trafficking patterns in the days immediately following injection. Generating such a 
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predictive model could help save time, financial resources, lower animal numbers, and in 
the long-term, provide a rapid proxy for vaccine efficacy during emerging outbreaks or 
military contexts where verifying immunity quickly is vital.  
 
In summary, understanding acute spatiotemporal trafficking in the days following vaccine 
delivery can aid in the rational design of vaccines during preclinical and translational 
vaccination studies. We demonstrate a dual radionuclide:near-IR platform to non-
invasively monitor non-human primate mRNA vaccine trafficking in a longitudinal, 
quantitative manner via PET/CT, while preserving downstream ability to investigate events 
at the level of single cells and tissue. As the RNA is directly labeled, the approach is highly 
modular and flexible, allowing any vaccine formulation to be utilized. In particular, using 
PET imaging in combination with cellular/molecular based tagging methods, such as 
barcoding, could prove powerful. Due to its non-invasive nature, we believe this vaccine 
monitoring approach can help reveal spatiotemporal determinants of vaccine efficacy in 
preclinical and translational vaccine studies, particularly in large mammals, where safety 




IVT mRNA labeling 
IVT mRNA encoding Yellow Fever prME was provided by CureVac AG (Tübingen, 
Germany). It included a 5’ cap, the 3' untranslated region (UTR) from human albumin as 
well as a poly(A) tail. MTRIPS for mRNA labeling were synthesized as previously 
described (1). Briefly, 15-17 nucleotide long 2’ O-methyl RNA-DNA chimeric 
oligonucleotides, containing three to four amino-modified thymidines, a short poly(T) linker 
and a 5’ biotin (Biosearch Technologies, Petaluma, CA) were purchased. Three 
oligonucleotides (termed CV1, CV2 and CV3) complementary to sequences in the human 
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Albumin 3’ UTR of the mRNA were used for annealing. The oligonucleotides were labeled 
with DyLight 680-NHS esters (Pierce) using manufacturer protocols, and excess dye was 
removed using 3kDa centrifugal filters (Millipore). 
The neutrAvidin core for MTRIPS assembly was conjugated to DOTA NHS ester (5X molar 
excess) in 0.1M-phosphate chelexed buffer and excess DOTA was removed using 10kDa 
filters. For radioactive labeling, NeutrAvidin-DOTA (Na-DOTA) was incubated with 64Cu in 
ammonium acetate for 1 hour. Unbound Cu64 was removed using 10 kDa filters. Finally, 
Na-DOTA was incubated with each fluorescently labeled oligonucleotide separately for 1 
hour at RT, at a 1:5 molar ratio. Excess oligonucleotides were removed using 30kda filters. 
For mRNA labeling with MTRIPS, 800ug mRNA were first heated at 75˚C for 10 minutes 
(to remove secondary structure) and immediately placed on ice for 2 minutes. MTRIPS 
were added to the mRNA and were incubated at 37˚C for 2 hours. The mRNA to MTRIPS 
ratio was optimized to 1:0.5, which ensured efficient mRNA labeling while avoiding the 
need for a final purification step by filtration. The resulting labeled mRNA was tested via 
HPLC (data not shown).  
 
Animals and intramuscular (I.M.) Injection 
Cynomolgus monkeys (age, n=4) were used in this study. Macaques were maintained in 
accordance with the regulations of the Guide for the Care and Use of Laboratory Animal 
at New Iberia Research Center, University of Louisiana. Each animal was injected 
intramuscularly in the right quadriceps with 500uL Ringer’s Lactate solution formulation 
CholK (In-Cell-Art, Nantes, France) with Yellow Fever (YF) prME IVT mRNA labeled with 
MTRIPS composed by DyLight 680-oligonucleotides conjugated to 64Cu NeutrAvidin. The 
total radioactivity injected was 0.7-0.9 mCi. Radioactive animals were housed in a 
separate, designated room, according to EH&S policies, with daily radioactivity measures, 
until 10 half-lives had elapsed (5.3 days for 64Cu).  
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PET/CT imaging of NHPs and Image Analysis 
Animals were imaged at 3.5 and 28 hours post injection on a clinical grade PET/CT 
scanner (Siemans Biograph 40 at Our Lady of Lourdes Regional Medical Center, in 
Lafayette, Louisiana). Specific PET parameters used during acquisition can be requested 
through the corresponding Author.  
All quantitative software analysis was completed from DICOM formatted images using 
MIM Software Inc. (Cleveland, Ohio). A high pass thresholding filter set at 28% (i.e. only 
the highest 72% of signal within a given region) was used to assign region of interests 
(ROIs) for each lymph node. These volumetric regions of interest were used to report 
average, maximum, and total standard uptake values (SUV) values. The volume of the 
ROIs for a given lymph node never varied by more than 5% across time points. To account 
for instrument parameters that might have altered between imaging sessions, contralateral 
muscle SUV average values for a circumscribed ROI (region of interest) were used to 
normalize readings. The video clip displaying a 3D reconstruction of the PET/CT data was 
accomplished through Amira software (Thermo Fisher Scientific, California).  
PET sensitivity estimation of mRNA 
The iliac LN of AF031 was used to estimate the sensitivity of PET/CT to quantify mRNA, 
as it was the lowest, yet detectable, organ able to be quantified. The calculations that 
follow are based on the SUV values for this iliac LN and an initial injection quantity of 
200ug of mRNA. Assuming a closed system (i.e. no RNA enters the blood circulation), 
then the amount of mRNA indicated by an SUV of 1.72 is 36.3ng. This iliac LN signal is 
11.80-fold greater than that found in an equal volume of control muscle tissue. If we 
assume a detection sensitivity 2x greater than background, then the sensitivity of detection 
appears to be 6.16ng for a volume of 0.4mLs, or 15.4 ng/cm3.  




Two of the four animals were euthanized at 28 hours post vaccine administration.  During 
necropsy, muscle tissues and lymph nodes were screened for near-IR signal using the 
Fluobeam near-IR portable camera (Fluoptics Imaging Inc, Cambridge MA). Images were 
acquired at varying exposure times in low ambient light conditions. Contralateral tissues 
were also collected as negative controls. Excised tissues were split in half, and dissociated 
for downstream flow cytometry, or fixed and snap frozen for tissue immunohistochemistry.  
For cell dissociation, lymph nodes (and spleen sections) were mechanically dissociated 
by pressing and grinding the tissue on top of a 70-micron filter, fitted on top of a 50mL 
conical tube. During this mechanical disruption, the tissue was systematically washed with 
RPMI media, under sterile conditions. After the lymph nodes appeared as a thin flat layer, 
the tissue was washed a final time, and the filtered cloudy solution within the 50mL tube 
was centrifuged at 1000xg for 10 minutes at 4°C. If the resultant cell pellet contained a top 
RBC layer, RBCS were lysed with addition of JAK solution for 5 minutes, and rewashed 
with RPMI. Cells were resuspended in 10mLs of RPMI, counted with a hemocytometer, 
and frozen at a concentration of 10-20 million cells/mL in 20% DMSO in FBS at a 
temperature gradient of -1°C/minute. Cells were stored and shipped at -80°C, and stored 
long-term in liquid nitrogen.  
For IHC tissue processing, macaque draining iliac or inguinal LNs, muscle (injection site 
and contralateral) and mouse iliac LN tissues were fixed in 4% PFA overnight at RT. The 
next day, the tissue was washed once with PBS and incubated with 30% sucrose in PBS 
overnight at 4°C, followed by OCT embedding. Tissue blocks in OCT were immediately 
snap frozen in dry ice cooled isopentane, and stored at -80°C. Frozen tissue blocks were 
sectioned using a cryostat in 10 micron tissue sections. Tissue sections separated by 50-
100 microns were used to stain for the specific immune cell markers and antigenic protein. 
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Macaque LN tissue from a sham animal (uninjected) and contralateral animal were used 
as controls.  
Immunofluorescence tissue imaging  
Cynomolgus monkey iliac LN tissue sections were stained for cell surface markers (Table 
2) and expressed YF prME antigen. The slides were thawed in a humidified chamber for 
5 minutes and washed with 1x PBS twice. The sections were incubated in 1x Dako antigen 
retrieval buffer for 30 minutes in a steamer followed by cooling at RT for 20 minutes. The 
slides were washed once with PBS (1x) and permeabilized with PBS with 0.1% Tween 20 
for 30 minutes. The tissues were blocked with 10% Donkey serum plus 1% BSA for 45 
min followed by incubation with the primary antibodies targeting selected cell type markers 
and YF prME protein for 45 minutes at RT (the primary antibodies source and dilutions 
are listed in Table 2). Tissue sections were washed four times with 1x PBST for 10 minutes 
each followed by incubation with the secondary antibodies (as listed in Table 2) for 30 
minutes. Slides were washed with 1x PBST four times for 5 minutes each and incubated 
with DAPI for 5 minutes at RT. After two final washes with 1x PBS, slides were mounted 
with 10ul of prolong gold. Muscle tissue sections were incubated with 1x DAKO antigen 
retrieval buffer for 20 minutes and blocked for 1 hour as previously described. Slides were 
incubated with primary antibodies for selected immune cells markers overnight. The next 
day, the tissue sections were incubated with secondary antibodies for 30 minutes, followed 
by three washings with PBST. The YF prME antibody was added for 1 hour followed by 
three washings with PBST. Nuclei were counterstained with DAPI and slides were 
mounted with Prolong Gold.  
LN and muscle tissue sections from macaques were imaged with a 40x, oil objective. 
Three or four slides were imaged for each cell marker and 10-12 images were taken per 
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slide. Stitching was performed using a 20X objective for LN tissue and a 40X objective for 
muscle tissue. 
Table 2: Immunofluorescence Staining Markers  
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Cryopreserved cells were thawed at 37°C, washed with two volumes of fresh RPMI, 
resuspended in 2 mLs 1x PBS, and counted with a hemocytometer. One million cells were 
chosen and stained with the lymphocyte activation panel indicated Table 3. Live dead 
staining was performed first, followed by surface cell staining, and finally permeabilization 
(saponin) followed by intracellular staining (All staining steps occurring in FACS Wash – 
2% FBS in 1x PBS. Cells were fixed with 1% PFA in FACS Wash at 4°C until data 
acquirement. In all cases, cells were gated for single cells via FSC-H vs FSC-A  SSC-A 
vs FSC-A for lymphocytes  Live/Dead stain. All samples were acquired using a Fortessa 
Cell Cytometer equipped with 405, 488, 560, and 640 laser lines (BD Biosciences). All 
analysis was performed using the FlowJo software package (Tree Star, Ashland, OR, 
USA). A total of at least 300,000 events were recorded for each organ. 
Table 3: Lymphocyte Activation Panel for Flow Cytometry 
Cell Marker Indicates Dye Clone (Company) 
CD3 T cells V450 SP34-2 (BD) 
CD4 T cells APC-H7 L200 (BD) 
CD25 Activated T cells  BV650 BC96 (Biolegend) 
CD8  T cells  FITC RPA-T8 (Biolegend) 
CD69  Activated T cells  BV786 FN50 (BD) 
CD20 B Cell BV711 2H7 (Biolegend) 
CD95 Fas Receptor BV605 DX2 (Biolegend) 






Statistics and Image Visualization 
For the comparisons of total SUV across time, the fold change in total SUV for a given 
lymph node was calculated. Both estimation (95% confidence interval) and null hypothesis 
significance testing via multiple comparison student T-tests were conducted at 95% 
significance to evaluate differences from a baseline fold change of 1x. For both CIs and 
student T-tests, the Bonferroni correction was applied. All statistical tests and graphical 
figures were generated using GraphPad Prism (La Jolla, California).  
RT-PCR for cytokine expression in vitro 
Hela cells (ATCC) were cultured in DMEM (Lonza) with 10% FBS (Hyclone), 100 U/ml 
penicillin, and 100 µg/ml streptomycin (Invitrogen) and were plated one day prior to 
experiments. Cells were transfected with 500ng unlabeled or MTRIP-labeled mRNA in 
duplicates using Lipofectamine 2000 (L2K, ThermoFisher Scientific) following the 
manufacturer instructions. Vehicle only controls were included. 24h post transfection cells 
were processed for total RNA extraction using the RNeasy mini kit (Quiagen). Total RNA 
was checked for integrity via agarose gel electrophoresis and quantified via 
Nanodrop2000. 1ug of total RNA was used for cDNA synthesis using the RT2 first strand 
kit (Quiagen) according to manufacturer instructions. 1ul of the reaction product was used 
for qRT-PCR using the Real-time RT2qPCR primer assay (SYBR green) in the presence 
of gene-specific primers for IL6, INF1B, IL1B and GAPDH (Quiagen). qRT-PCR was 
performed using the ABI StepOnePlus real time PCR system (Applied biosciences). 
 
Data Availability  
The authors declare that [the/all other] data supporting the findings of this study are 
available within the paper [and its supplementary information files]. PET/CT scanner 









Aerosolized mRNA transfection of the FRT mucosa to express antibodies 




Much of the preliminary anchored antibody and aerosol delivery in this chapter was 
developed in: Tiwari PM*, Vanover D*, Lindsay KE, Bawage SS, Kirschman JL, Bhosle 
S, Lifland AW, Zurla C, Santangelo PJ. “Engineered mRNA-expressed antibodies prevent 
respiratory syncytial virus infection.” *These authors contributed equally to this work. 




• The whole of the FRT can be transfected with naked mRNA and H2O 
• Expression occurs quickly, within 4 hours 
• Anchoring can retain antibody in tissue and secretions for at least 28 days  
o Antibody is detected throughout the FRT, including in the Uterus  
• Genitally expressed antibodies neutralize virus ex vivo and protect cervical biopsy 
explants from SHIV Challenge  





Human immunodeficiency virus (HIV) remains a large public health burden worldwide, 
with 36 million people infected and 1.8 million new cases per year81. The portal of virus 
entry can vary based on the route of transmission and geographic location, but in general, 
genital mucosal entry is most common, followed by i.v. drug use and mother to child 
transmission. In the case of heterosexual serodiscordant couples, the estimated 
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probability of infection of the female genital tract (FRT) is 1 in 200-2000 per coital act, 
although this probability is dependent on the current viral burden in the donor, which is 
highest during the acute and late stages of infection82,83. Recipient factors providing 
protection include mucus, antimicrobials present in genital secretions, intact tight junctions 
between epithelial cells, and protective mutations in the CCR5 co-receptor84. The 
increased use of anti-retroviral therapy (ART) to reduce the risk of transmission, both in 
the donor and receiver, has led to dramatic decreases in nascent HIV infections, with a 
protection rate of 90%. Both pre-exposure (PrEP) and post exposure prophylaxis 
regimens consist of a required daily use regimen, potential for nephrotoxicity, expensive 
cost, and a lack of coverage against other STIs. As such, alternative and potentially 
patient-applied approaches to treatment and prevention of HIV could prove useful, 
especially in regions where access to ART therapy is difficult to access.  
 
The mechanisms and kinetics underlying HIV acquisition in humans is inherently difficult 
to study. As a result, the simian immunodefiency virus (SIV) and chimeric simian-human 
immunodeficiency virus (SHIV) models in non-human primates (NHPs) are powerful 
models to examine acute infection, as the disease progression reliably follows the course 
of human HIV infection [Refs]. The only protein on the virion surface is the Env 
glycoprotein, a trimer of two non-covalently associated sub-units, gp120 and gp41, 
responsible for binding CD4 receptors on target immune cells and mediating membrane 
fusion, respectively. The HIV genetic variants most likely to successfully infect the host 
enrich for Env on the virion surface, increasing the probability of binding CD4+ cells85,86, 
which are located with varying frequencies throughout the entire submucosa of the lower 
FRT. These consist of predominately CD4 high expressing CCR5+ T cells87,88, but also 
CD4 low expressing dendritic cells and macrophages. Epithelial cells are not able to 
support productive infection. It is likely that inflammation, whether caused by co-infection 
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with other sexually transmitted infections, genital ulcers, hormonal birth control, or physical 
trauma, increases the risk of HIV transmission by recruiting T cells and dendritic cells 
(DCs) to the area89, while also activating T cells90. 
 
When virus is introduced into the FRT lumen via ejaculate, it rapidly permeates the 
vaginocervical epithelium by passive diffusion, perhaps as quickly as within 30 minutes91. 
After initial productive infection in CD4+ T cells, clonal amplification occurs and virus is 
able to spread more generally within the mucosa, and systemically to lymph nodes and 
mucosal associated lymphoid tissue (MALT)92. Alarmingly, there is also evidence that 
virus can reach systemic lymph nodes in under one day, suggesting that mucosal 
amplification is not necessarily required for HIV to reach systemic organs93. Dendritic cells 
don’t support productive infection themselves, but facilitate HIV transmission and 
dissemination by transferring CD4-bound-HIV to T cells located the mucosa and lymphatic 
organs94,95. Thus, it is critical that any intervention strategy counteracts initial virus seeding 
and replication in the lower FRT and regional lymph nodes. 
 
Active (vaccination) and passive (topical) immunization strategies are being deployed to 
protect patients from HIV. While not underplaying the importance of CTL and T helper cell 
responses for control and protection from HIV at mucosal surfaces, humoral immunity 
plays a considerable role against genital pathogens by providing a first line of defense at 
mucosal surfaces96. Antigen specific immunoglobulins present in the genital mucosa of 
vaccinated animals are a mixture of systemically derived97 and locally produced 
antibodies98. Local production occurs in the form of IgG+ cells99 consisting of sub-epithelial 
plasmablasts and ectopic follicles100,101, while systemic IgG reaches the FRT compartment 




Due to tight association with cervicovaginal mucus102, immunoglobulins (predominately 
IgA and IgG) mediate protection through neutralization103,104, along with a variety of Fc 
mediated mechanisms, including: slowing virion diffusion through mucus105,  antibody 
dependent cellular cytotoxicity of infected cells, activating complement pathways, virus 
opsonization, transcytosis inhibition104, cellular phagocytosis, and in the case of IgA, 
agglutination. For genital IgG in particular however, it appears neutralization of Env plays 
an outsized role in affording protection, compared to other antibody-associated 
mechanisms106. That said, certain non-neutralizing antibodies play a role in controling107 
and impacting viral seeding following vaginal challenge108, due to their diverse Fc 
mediated anti-viral activities109 .  
 
Binding of a neutralizing antibody to a single monomer of the Env trimer is sufficient to 
prevent the conformational changes required for membrane fusion, effectively neutralizing 
the entire spike in a single binding event82. Broadly neutralizing antibodies (bNAbs), which 
are characterized by their ability to neutralize a broad assortment of HIV strains with high 
potencies, correlate strongly with chronic viremic control, but only a minor fraction of 
infected individuals develop them110. Unfortunately, to date, no HIV vaccine has elicited 
host generated broadly neutralizing antibodies in uninfected inviduals106, although directed 
antibody evolution through engineered immunogens is an area of active research. Due to 
this, passive immunoprophylaxis by parenteral administration of bNAbs is a current 
stopgap, until HIV vaccines progress sufficiently.    
 
Human clinical trials involving passive transfer of bNAbs are promising, displaying control 
of viral loads in human patients111,112 and suppression of viral rebound after ART treatment 
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interruption113. Passive infusion of the CD4 binding site bNAb 3NBC117 even increased 
host generated antibody responses to HIV-1114. NHP studies demonstrate protection from 
mucosal SHIV challenge115–117, along with control of viral replication118–120. In one study, 
administration during acute SHIV infection led to long lasting CD8+ T cell immunity that 
suppressed virus long after administered antibody titers were undetectable121. In these 
passive immunotherapy based approaches, virus breakout occurs if serum antibody titers 
drop below threshold levels111 or antibody-resistant provirus strains evolve in the 
individual111–113. Escape viruses that emerge during passive therapy remain sensitive to 
bNAbs that target other non-overlapping domains112. LS-mutations in the Fc region of 
antibodies increase circulation half-life, and in a phase 1 clinical trial VRC01LS remained 
in circulation 4 fold longer than wild type VRC01122. 
 
To protect patients from acquiring HIV, ectopic antibodies delivered parenterally must 
reach the genital compartment through transudation from the serum.  It has been 
estimated based on empirical measurements that around 1/90th of the concentration of 
antibody in the serum is achieved in vaginal secretions82. The amount of bNAb required 
in genital secretions to prevent infection decreases with higher binding affinities. For the 
bNAb PGT121, with a relatively high binding affinity (kD = 0.086nM), genital secretion 
concentrations of as low as 30 ng/mL are estimated to provide neutralizing protection82. 
There also appears to be a time delay between the peak serum concentration of injected 
antibody (which is almost immediately) and the peak concentration in the vaginal 
secretions, although the magnitude of this delay is dependent on the specific 
antibody117,123. In effect, systemically administered bNAbs have demonstrated promising 
anti-viral properties. However, the large doses administered and uncertain time required 
for genital secretions to reach sufficient neutralization concentrations, suggests that local 
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application of bNAbs could prove useful. Direct vaginal application of bNAbs prior to 
challenge provided protection in NHPs124, but the half-life of such an approach is likely on 
the order of several hours125. 
 
In this study, we explored the potential use of the cervicovaginal mucosa as a platform to 
express mRNA encoded bNAbs locally, at the site of infection. Specifically, we 
demonstrate in sheep and rhesus macaques, the use of aerosolized naked mRNA to 
express PGT121 at high concentrations in the vagina and cervix. To promote the retention 
of bNAbs in the FRT, we incorporated a glycophosphotidyl inositol (GPI) membrane 
anchor to the heavy chain Fc domain of PGT121. In vitro data confirms that this membrane 
anchored PGT121 (termed aPGT121) leads to an outward facing cell surface display of 
PGT121 that is functionally able to bind SHIV virions. We detected aPGT121 in FRT tissue 
at the longest time point we measured, 28 days. In comparison, secreted PGT121 levels 
were comparable in the short term, but dropped off substantially by three weeks. The 
expressed PGT121 retains neutralizing capacity in secretions and in cervical biopsy 
explant SHIV challenge models.  
 
Aerosolized transfection deposits mRNA directly into the cytoplasm 
 
Pilot experiments in rhesus macaque genital mucosal surfaces and other comprehensive 
studies in mice lungs illustrate that aerosolized delivery to these mucosal surfaces 
results in robust protein expression. There is some evidence that hypotonic solutions 
increase transport from luminal spaces126. For this reason, and translational simplicity, 
we use a formulation of H20 with naked nucleic acids. However, the mechanism 





Figure 3.1: The in vitro transfection setup using the MADgic Teleflex aerosolizer 
attached to a high-pressure syringe. Media is removed directly prior to application of 
spray to plated on coverslips in 24 well plates.  
 
To investigate how naked mRNA is leading to robust protein expression via aerosol, we 
used a vertical in vitro setup (Figure 3.1) to transfect monolayers of adherent cells. The 
ideal distance to prevent cell dissociation from the applied pressures were sprayer 
dependent, and were determined to be 4.5 inches for the Teleflex and 1 inch for the 
microsprayer. After delivery with dye labeled mRNA, the fraction of nucleic acid not in the 
endosomal compartment or nucleus was estimated using microscopy at discrete time 
points after spraying (Figure 3.2). The markers CD63, Clathrin, Caveolin, EEA1, LAMP-1 
were used to demarcate early through late stages of the endosomal compartment, while 












Figure 3.2: Aerosol transfection of cells localizes the mRNA directly to the cytosol 
of cells. (A) Spraying of mRNA and pDNA in lipofectamine 2000 (L2k)resulted in GFP 
protein production at 24 hours. (B) mRNA led to more GFP production and more cells 
transfected than pDNA + L2k. (C) In vitro fluorescent imaging of dye labeled Mrna (green) 
alone and costained with endosome markers (red). (D) Less than 70% of the mRNA 
colocalizes with the pan stage endosomal markers CD63, Clathrin, Caveolin, EEA1, 
LAMP-1. (E) The proportion of mRNA in the cytosol does not change from 1 hours to 6 
hours post transfection. * p < 0.05 ;  **** p < 0.00005.  
 
 
The results indicate that GFP encoding mRNA is reaching the cytoplasm almost 
immediately upon delivery. Around 70% of the cellular mRNA is cytosolic at 15 minutes 
post-delivery (Figure 3.2D). There is a slight pattern of increased endosome localization 
over time (up to 6 hours), but these changes are not significant (Figure 3.2E). These 
72 
 
results suggest aerosol transfection is depositing naked nucleic acids directly into the 
cytosol. For mRNA, this results in access to translational ribosomal machinery, leading to 
protein expression. Preliminary data with aerosolized naked pDNA suggests direct 
deposition into the cytosol, with no transport to the nucleus, and thus no subsequent 
protein production (data not shown).  
 
Aerosolization of naked mRNA is required to transfect the cervix 
 
To explore the physico-temporal parameters of FRT transfection, we used sheep, an 
animal model that is used in contraceptive and vaginal implant trials due to a geometry 
that closely mimics the human FRT (as a point of reference, the sheep in our studies weigh 
~80-110 lbs). From the vaginal vestibule to the cervix is 8-10 inches. To visualize 
transfection, we delivered 250ug of Firefly Luciferase mRNA via the MADgic Teleflex 
aerosolizer to the FRT. After 24 hours, the entire FRT was removed, D-Luciferin substrate 
applied, and IVIS used to record bioluminescence signal (Figure 3.3). As an alternative 
delivery method, mRNA was squirted by high-pressure syringe onto the cervix. Robust 
transfection of the cervix was observed by aerosolization, but no signal was detected when 




Figure 3.3: Aerosolized naked luciferase mRNA transfects the sheep cervix. 250ug 
of Firefly luciferase encoding mRNA was sprayed in a single dose onto the cervix. 
Statistical comparison was completed using two tailed Mann-Whitney non-
parametric analysis.  
 
 
PGT121 antibody anchored to the membrane of cells functionally binds SHIV 
 
In work that was is covered in Tiwari & Vannover et al., Nature Communications, I have 
modified the heavy chains (HC) of antibodies with the post-translational modified GPI 
anchor. GPI anchors, in this case for decay accelerating factor (DAF), are commonly used 
in nature to associate proteins to the outside surface of the plasma membrane. There is 
as of yet no published literature on using GPI anchored antibodies for in vivo purposes.  
 
In both Palivizumab and PGT121 heavy chains, correct association with the light chain 
(LC) and binding to target antigen is still retained after addition of the DAF GPI anchor on 
the 3’ end of the primary HC transcript (5’ terminal DAF anchors inhibited folding with the 
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light chain). Whole antibody localizes to the surface when aHC (anchored HC) and the 
light chain mRNA are both delivered (Figure 3.4). The delivery of a single chain alone 
does not lead to abundant protein expression.  
 
 
Figure 3.4: aPGT121 is displayed efficiently on the surface of transfected cells only 
when both heavy and light chains are expressed. mRNA encoding for each antibody 
chain were delivered via L2k transfection and fixed 24 hours post transfection. Blue – 
DAPI ; White – anti-human secondary 
We next tested whether aPGT121 (anchored PGT121) is functional while on the outside 
surface of cells. Fluorescently labeled SHIV virions were added to cells transfected with 
aPali or aPGT121. Only aPGT121 transfected cells bind SHIV and capture it at the cell 






Figure 3.5: Transfected cells displaying aPGT121 on their surface are able to bind 
SHIV virions. Cells were transfected with PGT121 mRNA and 24 hours later dye 
labeled SHIV was added to the cultures. RSV neutralizing aPalivizumab (aPali) antibody, 


























Visualizing mRNA transfection through PGT121:NanoLuc Fusion protein 
 
 
Figure 3.6: Schematic of the PGT121:NanoLuc fusion protein; in secreted and 
anchored forms. Total MW of anchored PGT121:NanoLuc is 195kD.  
 
 
The primary aim of this project was to express PGT121 in the FRT epithelium. To ensure 
that experimentally relevant epithelium tissue was being examined for protein 
quantification, a real-time method was needed to screen for positive tissue during 
necropsy and tissue processing. The luminescence reporter NanoLuc was fused to the 
LC of PGT121 on the 3’ end. NanoLuc is 100x more sensitive, does not use ATP during 
reaction with its substrate, and is only 19kD in size, as compared to Firefly Luciferase 
(Figure 4.6). Secreted PGT121:NanoLuc was isolated by gentle protein A/G purification 
of the supernatant after transient transfection of adherent cells. The dynamic range for 
PGT121:NanoLuc was found to be nearly 6 orders of magnitude from serial dilutions. In 
an adapted gp120 ELISA assay (consisting of all regular ELISA steps, with the substitution 
of NanoLuc substrate in lieu of detection antibodies), a sensitivity of around 500 pg/mL 
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was observed, on par with ELISA readouts, but with a greatly expanded dynamic range 
(Figure 3.7).  
 
Figure 3.7: Luminescence output from serial dilutions of secreted PGT121:NanoLuc 
in PBS (green) and a modified HIV gp120 ELISA (blue line). A high dynamic range and reasonable 
sensitivity is observed. The relationship between luminescence output and protein concentration 
follows a power model.  
 
Determining the optimal dose of PGT121:NanoLuc mRNA in the FRT 
 
To determine if sheep FRT epithelium is amenable to higher doses of mRNA during 
aerosolized transfection, a single 300uL spray of base modified 1-methyl-psuedoUridine 
mRNA transcripts, one for the heavy chain and the other for the light chain of PGT121, 
was delivered to the cervix of sheep. Three animals received 250ug of mRNA, and 
another three received 750ug of total mRNA. 24 hours after delivery, the entire sheep 
FRT was extracted. 2mLs of NanoLuc substrate was applied to entire vaginal, cervix, 
and uterus. IVIS imaging was used to measure the location and amount of luminescence 
in each animal (Figure 3.8). Luminesce near the cervix is higher in all 750ug animals 
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(Figure 3.8 A&B). Interestingly, the average radiance for each dosing group is fitted by a 





Figure 3.8: mRNA dose escalation in sheep FRT epithelium. (A) IVIS images of the 
FRT epithelium after a single mRNA dose at the cervix, 24 hours after transfection. All 
images are equally contrasted. (B) The average radiance at the cervix over the average 
radiance in the control animal. (C) A simple linear regression models the relationship 








Cervical and vaginal epithelium can be transfected by aerosol 
 
Now that we established that 750ug of mRNA is the minimum amount of mRNA that we 
should deliver, we wondered if both vagina and cervix are equally receptive to 
transfection. Two sprays, 750ug each, were delivered sequentially: one dose to the 
cervix, followed by a 3-4cm retraction of the speculum and spraying of the vagina. The 
signal was evaluated via IVIS imaging 24 hours after delivery in two animals. In both 
animals, protein expression was detected throughout the vagina and cervix. Collectively, 
34% and 53% of the entire lower FRT was successfully transfected, using two sprays. 
The luminescence intensities in the vagina and cervix were also similar (Figure 3.9). This 
data suggests that both the vagina and cervix can be transfected via aerosol mRNA 




Figure 3.9: Sheep vagina and cervix are transfected with similar effectiveness. 
PGT121:NanoLuc mRNA was sprayed in two consecutive 750ug doses - one at the 
cervix, then after a 3-4cm retraction, a second dose at the vagina. Red circles indicate 







Anchored antibody is retained in FRT tissue for at least 28 days 
 
Our next goal was to quantify and compare the tissue and secretion distribution of the 
anchored (aPGT121) and secreted forms (sPGT121) of PGT121 over time. Our 
hypothesis was that anchored PGT121 would remain in the mucosal epithelium 
longer than wild type secreted antibody. We compared secreted and anchored 
PGT121 constructs at 14 days and 28 days post transfection. 1.5mgs in total was delivered 
to each animal, 1x 750ug dose at the cervix, followed with 1x 750ug dose in the vagina. 
Genital secretions were collected longitudinally on a weekly basis to assess the amount 




Figure 3.10: Anchored antibody remains in the FRT mucosal epithelium at 28 days 
post-transfection. (A) IVIS imaging of the extracted lower FRT at 14 days and 28 days. 
(B) The average radiance relative to a control animal. Error bars represent ± SEM. 
 
 
IVIS was used following FRT removal to assess the retention of PGT121 for anchored and 
secreted constructs out to 1 month (Figure 3.10). Representative images for each time 
point and group are displayed (Figure 3.10A), along with quantification of the average 
81 
 
radiance relative to a naive control animal (Figure 3.10B). The luminescence signal in all 
aPGT121 tissues (n = 6), even at 28 days, is higher than sPGT121 tissues. These results 
support the notion that anchoring the antibody to the membrane surface differentially 
retains the antibody in the epithelium, at least for 1-month post-transfection. It also 
appears that the strongest source of signal is near the cervix, perhaps due to epithelial 
shedding differences between the vagina and cervix. Note that although sPGT121 28-day 
animals were originally scheduled, after assessing the low signal results at 14 days, it was 
determined that the animals could be repurposed.  
 
Quantitative western blot was the assay used to determine the exact amount of PGT121 
in the FRT epithelium (Figure 3.11). A standard curve using purified PGT121:NanoLuc 
was included in each blot. From each FRT explant, regions of caudal vagina, rostral 
vagina, cervix, and uterus were removed, using the IVIS signal as applicable. The tissue 
was dissociated using physical pulverization, homogenized with a bead mill, then lysed in 
RIPA buffer. Detection antibody against NanoLuc were used to quantify, in lieu of 
antibodies targeting human Fc, as apparent alterations in the Fc of sheep expressed 
PGT121 abrogated epitope binding. We speculate that glycosylation differences between 
sheep and humans Fc domains resulted in hiding of the target epitope of anti-human Fc 
antibodies. Another rationale for using western blot to quantify is that it seems the enzyme 
NanoLuc lost activity over time after processing of tissue. This became apparent upon 
downstream assays to measure PGT121:NanoLuc concentrations via luminescence (data 
not shown). This diminishing activity is either due to factors located within the in vivo 







Figure 3.11:  aPGT121 is present at high concentrations in all regions of the FRT at 
28 days post-transfection. (A) aPGT121 concentrations in excised cervix, vagina, 
uterus, and caudal vagina were estimated using quantitative western blot (B) Western blot 
demonstrating the characteristic aPGT121 band at 195kD for all regions of the FRT, 
compared to control cervix. 
 
 
Surprisingly, similar quantities of antibody appear to be in each section of the FRT, for a 
given animal (Figure 3.11A). Considering that only rostral vagina and cervix were targeted 
with the 2 doses of mRNA, this data suggests that free aPGT121:NanoLuc is localizing to 
these other regions of the FRT. It should also be noted that the rank order from highest to 
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lowest of animal 420, 461, and lastly 456, is the same rank order observed from the IVIS 
imaging of Figure 3.10B (although the differences weren’t nearly as large as that observed 




Membrane anchoring results in increased concentrations of PGT121 in vaginal 
secretions over time 
 
Quantitative western blots were also used to quantify the amount of PGT121 present in 
the vaginal secretions of sheep (Figure 3.12 – please note that the colors used in the 
anchored animals align to the same animal colors used in Figure 3.11). Anchored PGT121 
was detectable out to 28 days post transfection, with average concentrations of 40ug/mL. 
Secreted PGT121, meanwhile, was only barely above the level of detection at 14 days 
post transfection. The maximum mean concentration of PGT121 was achieved at 24 
hours, with 210ug/mL and 80ug/mL, for anchored and secreted PGT121, respectively.  A 
limitation of this longitudinal sampling however is that we removed a given amount of 
protein each time we sampled, from a source that was finite (since mRNA encoded protein 







Figure 3.12: aPGT121 is present in vaginal secretions up to 28 days post 
transfection. Three sheep were transfected with two doses of 750ug of mRNA encoding 
for aPGT121. Secretions were collected at 1, 7, 14, 21, and 28 days post-transfection. (A) 
Longitudinal sampling of PGT121 concentrations over time, for all animals. (B) The mean 
concentration of PGT121 at each timepoint. (C) Antibody concentration was quantified via 
Western Blot analysis, using a standard curve of purified PGT121:NanoLuc protein. The 
expected size of aPGT121:NanoLuc was confirmed to be around 195kDa. The 
representative image displayed is for animal 420. For secreted antibody, the LC was more 













Rhesus Macaque Studies 
 
Up to this point, we have characterized the spatiotemporal patterns of mRNA transfection 
and the kinetics of protein expression in vivo. The expressed bNAb PGT121 was 
detectable at relatively high concentrations, up to 28 days using the anchored construct. 
This robust expression was demonstrated in sheep, which is relevant due the geometric 
similarities between sheep and human FRTs. The device used was an off-the-shelf 
aerosolizer, which sells for less than $10. The transfection medium consists of RNA in 
water.  
 
The next logical step is to study protection from SHIV challenge in rhesus macaques. 
However, the number of animals needed to power such a study will require additional 
funding. In the meantime, we decided to perform appropriate ex vivo assays that could 
provide preliminary evidence indicating efficacy.  The data that follows was conducted on 
three female rhesus macaques that were sprayed with 250ug of aPGT121 mRNA. Two of 
the monkeys (RWg13 and RVg13) received a 1:4 ratio of LC to HC, while RCo13 received 
only aPGT121 HC mRNA. It should be noted when interpreting the data, that heavy chain 
alone can still bind virus, so while a useful comparison, is not a true negative control.  
 
 
PET/CT imaging reveals trafficking to systemic lymph nodes within 70 minutes 
 
 
There is evidence that HIV/SHIV introduced into the FRT rapidly ‘seeds’ distal sites 
beyond the local mucosal tissue. Thus, any therapeutic delivery method would ideally also 
localize the intervention at the same local and systemic sites as the virus. To test whether 
aerosolized mucosal mRNA traffics to draining lymph nodes, we labeled PGT121 mRNA 
with the orthogonal 64Cu labeled probes, as was described in Chapter 2. Radioactive 
mRNA was sprayed in two doses, once on the cervix and a second dose in the vagina, in 
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three rhesus macaques. PET/CT imaging was performed at 70 minutes, 4 hours, 24 hours, 
48 hours, and 72 hours post administration (Figure 3.13) 





Figure 3.13: PET/CT imaging of rhesus macaque RVg13 after radioactive mRNA 
aerosolized transfection of the FRT. mRNA was labeled with 200uCi of radiation. (A) 
Representative PET images at 75 minutes and (B) 24 hours post transfection. Numbers 





Trafficking to lymph nodes at the earliest imaging session, 75 minutes after aerosolized 
delivery, suggests mRNA is already leaving the cervicovaginal epithelium and reaching 
distal sites. Perhaps due to the large surface area of the FRT, these nodes are not 
confined to a single anatomical region. Rather, sacral, popliteal, inguinal and femoral, iliac, 
para-aortic, and mesenteric lymph nodes all contain detectable signal.  
 
After 48 hours, the signal in the lymph nodes is no longer detectable, most likely due to 4 
half-lives of radioactive decay. However, significant signal is still detected at the FRT 
mucosal surface at 72 hours (Figure 3.14), suggesting retention of mRNA transfected cells 
within the FRT. The mRNA is likely actively being degraded by RNA nucleases by 72 
hours, but the chelated oligo probe is base modified and nuclease resistant, and thus 






Figure 3.14: Radiolabeled mRNA is retained in the FRT following transfection. Two 
125ug doses of 64Cu labeled aPGT121 mRNA were delivered via aerosol to first the cervix, 
then ~ 3-4cm caudally in the vagina. PET/CT imaging over 3 days was used to monitor 
mRNA biodistribution. (A) representative PET/CT images from 75 minutes to 72 hours. 
(B) The total SUV in the FRT over time. (C) The ratio of the total SUV in the FRT to the 







The cervical Os, which is our visualization target during speculum insertion, can also be 
resolved in the CT images. While not surprising, but nonetheless reassuring, the focal 
point of mRNA transfection appears to be the Os. Interestingly, using the radioactive signal 
also provides insight into gauging the efficiency (ie the amount of mRNA dose that is being 
‘wasted’) of the current delivery method. Between 70 minutes and 4 hours, the amount of 
PET signal in the FRT space decreases by ½ to  2/3. After this initial rapid decrease, the 
SUV decrease from 4 hours to 72 hours is less drastic and resembles a more linear 
process.  I believe the cause of the rapid decrease over the first 4 hours is due to excess 
mRNA that did not transfect the FRT epithelium. This suggests to me that using 350uL 
volume doses is simply too much in the much smaller confines of the rhesus macaque 
vagina. It is not suprising that aerosol parameters will need to be modified for future non-
human primate studies and that the data that follows is not optimized (I will bring this 
optimization point again later on).  
 
Cervicovaginal biopsy explants demonstrate protection from SHIV challenge 
 
Secretions from the three animals were collected prior to transfection, and post-
transfection at 4 hours, 24 hours, 48 hours, 72 hours, and 7 days. Biopsies were collected 
at 1 day and 3 days post transfection, with one sample taken from the cervix and two from 
the vagina, at each timepoint. Because of the uncertainty involved with performing 
biopsies (i.e. is the correct spot being sampled), the extracted explants were screened for 





To provide some indication of protection, biopsy explants from aPGT121 transfected FRTs 
were challenged with SHIV162p3, which is a Clade B Env virus. 5.5x104 TCID50 (50% 
tissue culture infectious dose) of virus at a 1:1 ratio was added to each explant, incubated 
for 2 hours, washed, then cultured out to 10 days. Supernatant was collected at 4, 7, and 
10 days post-challenge and assayed with a SIV p27 ELISA to determine if productive 
SHIV infection developed.  With this assay workflow, we could determine both the 






Figure 3.15: aPGT121 protects biopsy explants from SHIV162p3 challenge. 250ug of 
aerosolized aPGT121 mRNA was delivered to the cervix and rostral vagina of three rhesus 
macaques. Biopsy explants were removed from cervix and vagina at 24 and 72 hours post 
transfection, screened for luciferase activity, and then challenged with SHIV162p3. (A) 
p27 ELISA quantification of the explant supernatants, separated by animal and time point. 
A colored line indicates infected vaginal (red) or cervical (blue) tissue, and these colors 
remain designated throughout the other panels. (B) A logistic fit was used to model the 
relationship between infection status (p27) and transfection status (luciferase activity) for 
each explant, at 24 and 72 hours. (C) Separating explants based on transfection status 
indicates that 100% of non-transfected tissues became infected, while only 11.1% of 




The main takeaway from Figure 3.15 is that the ability to separate explants based on 
transfection status, suggests that 100% (3 out of 3) of non-transfected vaginal samples 
became infected, while only 11.1% of transfected tissue were vulnerable to infection (1 
out of 9 explants). It should be noted that the biopsy explant SHIV Challenge model is by 
design a ‘worst-case scenario’ that removes many natural barriers to infection, including 
mucus, secretions, and epithelium. In a natural in vivo infection setting, the virus is 
introduced in the lumen, and then must percolate through the epithelium to CD4+ cells 
that reside in the sub-mucosa. In the case of a biopsy in vitro challenge, the virus has 
direct access to CD4+ cells from all directions, theoretically being able to bypass the 
transfected surface epithelium.   
 
Genital secretions from aPGT121 transfected animals neutralize SHIV in vitro 
 
 
Figure 3.16: Genital secretions from aPGT121 transfected animals neutralize SHIV 
within 4 hours 
 
Next, genital secretions collected over the course of a week were evaluated for their ability 
to neutralize SHIV through the TZM-bl Neutralization assay (Figure 3.16). Secretions 
demonstrated an ability to neutralize SHIV162p3 (Clade B) and SHIV2873Nip (Clade C) 
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at all time points measured, out to 1 week. Critically, secretions at 4 hours post-
transfection contained substantial neutralizing activity. The kinetics over time for the heavy 
chain only (RCo13) construct suggest that without association of the constant regions of 
the HC and LC, retention of antibody in the secretions is attenuated.  
 
This monkey data should be interpreted with some context, due to study constraints. First, 
dose and delivery optimization, as was performed in the sheep, was not possible the 
rhesus macaques due to the low animal numbers. Dose, speculum design, and dose 
volume are all variables that would need to be optimized. Nevertheless, the positive results 
indicated from explant challenge and secretion neutralization bode well for future SHIV 
challenge, especially if one considers the two would act in concert in an in vivo setting. As 
the dose escalation data suggests with the sheep, exploring the maximum dose and 






The vaginal mucosal has been explored in vaccination and therapeutic contexts to deliver 
drugs both locally and systemically. The lower FRT displays beneficial properties for drug 
delivery, including a large surface area, a high degree of vascularization, avoidance of first 
pass metabolism of the liver, good drug permeability, and is accessible enough to allow 
self-application5. Intra-vaginal application has been used to deliver hormones, anti-
microbials, and spermicides, packaged in the form of creams and gels, tablets and 
suppositories, vaginal rings, and mucoadhesives. For local treatment of FRT conditions, 
however, the high tissue permeability and vascularization likely lowers the resident half-




The amount of PGT121 required in the cervicovaginal mucosa to provide protection is 
unknown. Previous studies measured the amount of bNAb in the genital secretions, but 
did not ascertain FRT tissue concentrations, and how these levels relate to secretion 
concentrations and correlate with protection. Since the source of PGT121 in genital 
secretions are mRNA transfected epithelial cells, the amount of aPGT121 contained within 
the FRT mucosa will contribute to virus neutralization.  
In sheep, genital secretion aPGT121 concentrations remained well above the predicted 
IC50 concentration of 30ng/mL for 28 days, peaking at 200ug/mL by 24 hours, and 
remaining above 30ug/mL 28 days post-transfection. Epithelial aPGT121 was detected 
ubiquitously throughout the FRT at 28 days, although the significance of these amounts 
is hard to comment upon without in vivo challenge data.  
 
In this aerosolized mRNA transfection platform, the localized production of transgene 
protein by the native epithelium ensures that high tissue and secretion concentrations are 
achieved quickly, while also ensuring host glycosylation and other post-translational motifs 
are preserved. The addition of a membrane anchor retains the expressed protein in the 
epithelium. The formulation used in these experiments was a simple mixture of mRNA in 
water. The hypotonicity of water relative to host secretions may assist with fluid uptake 
into the FRT epithelium126. When stored lyophilized, mRNA is extremely stable and is not 
dependent on cold chain storage conditions128. The robust transfections we observed, 
simplicity of the aerosolizer, low cost of IVT mRNA, and stability of lyophilized mRNA, all 
support the potential for a use-on-needed, patient self-applied platform. This transient, 
spray based approach also holds social promise because of its ‘invisible’ nature - a third 
party or partner would never know that the woman was using this as a prophylactic, 




The FRT epithelium structure varies spatially in regard to thickness, immune cell 
types99,129, and frequencies of susceptible cells, and thus have differential probabilities of 
a productive infection developing. However, once surface area is considered, all areas of 
the lower female reproductive tract can be considered vulnerable to infection. Thus, it is 
favorable if prophylactic approaches protect the entirety of the lower FRT. In this study, 
we detected high concentrations of anchored PGT121 28 days after transfection in the 
uterus, cervix, and the vagina. The DAF GPI membrane anchor is not a permanent tether 
and proteins can be released from the surface of transfected cells by endogenous 
glycolipidases130. 
 
Parenteral administration of antibodies post-exposure can reduce downstream viral load 
setpoints131. The rapid expression times observed in sheep and rhesus macaque models 
(less than 4 hours) suggests that this aerosolized mRNA transfection platform could be 
used as an acute therapeutic measure at the site of infection. Assuming that 
cervicovaginally expressed bNAbs have the potential to follow the same diffusion and 
trafficking routes as cell free virions, the possibility exists for it to be used in combination 
with parenteral bNAbs to prevent or attenuate initial virus seeding. PET/CT tracking of 
mRNA further suggests that mRNA reaches systemic lymph nodes within 70 minutes; 
whether this mRNA is translated to protein in these secondary lymphoid organs is 
unknown.  
 
Packaging multiple drugs into a single formulation can prove tricky for nanoparticles, due 
to varying physical and chemical properties that impact stability132. Using mRNA provides 
flexibility, as any theoretical combination of neutralizing or non-neutralizing antibodies can 
be expressed simultaneously. Because we delivered the light chain and heavy chain 
encoding mRNAs as separate transcripts, we have already demonstrated expression of 
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two mRNA transcripts simultaneously, suggesting the potential for multiplexing during 
delivery.  
 
Combining bNAbs that target non-overlapping gp120 and gp41 epitopes results in additive 
effects on neutralization breadth133,134, and thus lower the effective concentrations 
required for neutralization. There is some evidence that chronic controllers do this 
naturally and develop multiple bNAbs targeting different, non-overlapping sites on Env110 
to suppress virus. To prevent possible escape mutation strains, using optimal CD4bs, V3, 
and MPER targeting antibodies simultaneously could result in IC50’s as low as 0.01ug/mL, 
with 100% breadth135. Alternatively, bispecific and trispecific ScFv’s consisting of the 
binding domains of multiple bNAbs, increase the breadth of coverage and display high 
binding affinities, and can be expressed from a single mRNA transcript that is comparable 
in size to the ones used in this study136. Other sexually transmitted infections that correlate 
with HIV, such as herpes, hepatitis, and genital warts (HPV), could also be targeted with 
relevant antibodies or anti-microbial peptides.  
 
This study suggests a complementary approach to large dose systemic antibody injection 
to achieve rapid (less than 4 hours) and long lasting (at least 28 days) neutralizing antibody 
concentrations within the lower female reproductive tract of sheep and non-human 
primates. The entire lower FRT was conducive to transfection, but demonstrates 
differential retention of encoded antibody, most likely reflective of differential rates of 
epithelial shedding. Further, we demonstrate that although the majority of mRNA remains 
in the FRT, aerosolized mRNA transports to distal lymph nodes quickly, albeit at low 
amounts. Tethering PGT121 to the transfected cell surface using a GPI anchor promoted 
genital secretion and tissue concentrations to remain well above neutralizing 
concentrations at 28 days post transfection. Ex vivo challenge of RM FRT biopsy explants 
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with SHIV demonstrates tissue level protection due to aPGT121 tissue expression, as well 
as antibody neutralization activity in secretions. These data provide a firm basis and 




IVT mRNA Synthesis 
 
The anchored and secreted PGT121 sequences were ordered as a DNA gBlock from IDT 
containing a 5' UTR with Kozak sequence, a 3' UTR derived from the mouse alpha globin 
sequence, and extensions to allow for Gibson assembly. The sequences were human 
codon optimized on the IDT website. The gBlock was cloned into a PCR amplified pMA7 
vector through Gibson assembly using NEB Builder with 3x molar excess of insert. All 
reaction transcripts were 0.8% agarose gel purified prior to assembly reaction. 
Subsequent plasmids from each colony were Sanger sequenced to ensure desired 
sequence fidelity.  
 
Plasmids were linearized with NotI-HF (New England BioLabs) overnight at 37 °C. 
Linearized templates were purified by sodium acetate (Thermo Scientific) precipitation 
before being rehydrated with nuclease free water. IVT was performed overnight at 
37 °C using the HiScribe T7 kit (NEB) following the manufacturer's instructions. RNA 
product was treated with DNase I (Aldevron) for 30 minutes to remove template and 
purified using lithium chloride precipitation (Thermo Scientific). RNA was heat denatured 
at 65 °C for 10 minutes before being capped with a Cap-1 structure using guanylyl 
transferase (Aldevron) and 2'-O-methyltransferase (Aldevron). Transcripts were then 
polyadenylated enzymatically (Aldevron). mRNA was then purified by lithium chloride 
precipitation, treated with alkaline phosphatase (NEB), and purified again. Concentrations 
were measured using a Nanodrop. Quality control measures include RNA agorose 
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electrophoresis to confirm purify, size distributions and poly(A) tail length, and in vitro 
transfection to confirm efficient translation of delivered mRNA. Transfection methods 
included aerosolized delivery to a monolayer of cells and Lipofectamine 3000 
(Thermofisher, CA) based transfection. Confirmation of protein production depended on 
the particular protein being expressed, but generally involved luminescence reading on a 
plate reader and/or immunofluorescence detection via microscopy at least 4 hours post 
transfection (substantial protein is present by 3 hours).  
 
In vitro Aerosol Transfection 
Adherent cells were plated in 24 well plates the day prior to transfection so as to be 80% 
confluent at the time of aerosol transfection. Media was removed directly prior to 
application of spray. A total volume of 50uL (MicroSprayer) or 200uL (Teleflex) of mRNA 
in water was applied to the cells, at a nozzle to cell surface distance of 2 inches 
(MicroSprayer) or 4.5 inches (Teleflex) ; these distances are required to prevent cell 
dissociation from the plate surface during spraying. 500uL of media was reapplied to the 
cells. For fixation, cells were washed 1x with PBS, incubated with 4% PFA at room 
temperature for 10 minutes and washed again with PBS. Permeabilization was carried out 
using 0.1% Triton X in PBS for 5 minutes at RT. Blocking was performed using 5% BSA 
in PBS at RT for 30 minutes. Primary antibodies were diluted in PBST and incubated at 
RT for 30 minutes. After washing 3x, secondaries were added at RT for 30 minutes. After 
DAPI counterstaining, coverslips were mounted with prolong gold medium and the edges 













6 – 18 month old female sheep (weighing 80-110 lbs) were housed at the Mississippi State 
University College of Veterinary Medicine.  
 
 
Speculum and Sprayer Equipment 
The MADgic Teleflex (referred to as Teleflex from here on out) pediatric atomizer is 
purchased individually contained within sterile packages. The dead space on the devices 
was determined to be ~170uL. mRNA solutions at the desired concentrations were loaded 
into a high pressure 1mL catheter syringe (MedLine). The end of the syringe was outfitted 
with a stopper plug. Teleflex and syringes were then attached via Luer Lock. A washer 
was attached to the end of the Teleflex tip to ensure proper centralization of the nozzle 
within the barrel of speculum. Using this setup, the Teleflex nozzle remains situated 5mm 
away from the distal end of the speculum.  
 
Aerosolized mRNA delivery  
Sheep were sedated using 500uL i.m. injections of Xylazine. After 3-5 minutes, animals 
were positioned in a supine position on a flat table. A polyethelene speculum, with an 
internal diameter of 3mm, was positioned by a Theorongolist until the cervical Oss was 
visible. Mucus was cleared away by brief surface cleaning with a Qtip applicator. The 
Teleflex, with dosing syringe, was then inserted into the tube until the distal nozzle of the 
aerosolizer was 5mm from the distal opening of the speculum. Hand pressure was then 
used to spray the mRNA. If vagina was also being sprayed in the same animal, the 
speculum was removed in a caudal direction by 1.5-2 inches, surface cleaning was 
performed, and vagina sprayed with a freshly loaded dose of mRNA. Average volumes 
delivered ranged from 300-450uL, based on the particular experiment. Speculums were 
sterilized in between animals, to minimize potential cross contamination. All controlled 
substance doses, mRNA doses, times of administration, and other experimental notes 





Weck-cell sponges (Beaver Visitech) were presoaked with 50uL of 1x PBS. If multiple 
sites within the lower FRT were sampled simultaneously, the sponges were connected 
together using surgical suture. With the animals upright and non-sedated, vaginal 
secretions were collected by positioning the sponge in the desired location and waiting for 
3 minutes. Sponges were placed into 1.5mL ependorfs and frozen at -80°C until analysis. 
To extract secretions from the sponges, the sponges were first placed into pre-weighed 
Qiashredder filters and centrifuged at 20,000xg for 10 minutes at 4°C. 200uL of extraction 
solution (IGEPAL, protease inhibitor in PBS) was added to the sponge and placed on ice 
for 15 minutes. The sponge was then spun at 20,000xg for a further 30 minutes. Secretions 
were alliquoted and stored at -80°C.  
 
IVIS Imaging  
The excised female reproductive tract was cut along a single edge so the entire surface 
area of the vagina and cervix lay flat. 2mLs of a fresh 1:40 solution of NanoGlo Substrate 
(Promega) in 1x PBS was added to the entire vagina and uterus. After 1 minute at room 
temperature, the organ was imaged with an IVIS. The positive portions were identified 
from the images, and carefully excised. The tissues were then either snap frozen in liquid 
nitrogen if protein analysis was the goal, or for microscopic analysis the tissues were 
placed in 4% PFA overnight at 4°C.  
 
Western Blot 
Tissues were weighed and snap frozen on liquid nitrogen before being crushed using a 
BioPulverizer (BioSpec Products). Radioimmunoassay (RIPA) buffer (Thermo Scientific) 
was then added at a ratio of 2 µL to 1 mg. This solution was then further homogenized 
using a bead mill (Next Advance) before being centrifuged at 16,000 xg for 20 minutes. 
Lysate supernatants were then aliquoted and stored frozen at -80 °C. Lysate protein 
concentrations were determined using a bicinchoninic acid assay (BCA, Pierce).  50 µg of 
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tissue lysates or a known amount of purified PGT121 were heat denatured for 10 minutes 
at 70 °C in 4x Loading Buffer (Li-Cor). Lysates and a Chameleon Duo ladder (Li-Cor) were 
loaded into wells of a 4-12% bis-tris polyacrylamide gel (Thermo Scientific) and separated 
at 200 V for 32 minutes on a Mini Gel Tank (Thermo Scientific). Proteins were transferred 
onto nitrocellulose with 0.45 µm pore size (Thermo Scientific) for 1 hour at 12 
V.  Membranes were blocked for 1 hour in Odyssey Blocking Solution (LiCor) before being 
incubated with primary antibodies, diluted in blocking buffer with 0.1% Tween-20 (VWR) 
overnight at 4 °C. Membranes were washed 3 times for 5 minutes each at RT with PBS 
containing 0.1% Tween-20 (PBST). Membranes were then incubated in secondary 
antibodies, diluted in the primary antibody diluent, before being washed again in the same 
manner. Membranes were then imaged on a LiCor Odyssey Cx imager and analyzed 
using the Image Studio software. 
 
gp120 ELISAs  
Recombinant gp120JR-FL (MyBioSource) was coated into 96 well microtiter, high binding 
plates (CoStar) at a concentration of 2 ug/mL, overnight at 4°C. The plates were washed 
4x with PBS-Tween 20 (0.05 %). Blocking was carried at room temperature for 2 hours 
with 2.5% BSA in PBS-T. Samples and standards were diluted appropriately in PBS-T and 
incubated overnight at 4°C. A standard curve was ran using Protein A purified whole 
PGT121-NanoLuc antibody from transient mRNA transfected in vitro transfection of 
adherent cells.  After washing, goat anti-human IgG Fc conjugated with alkaline 
phosphatase (Thermo) was added to the plates at 1:1500 and incubated at 37°C for 90 
minutes. A final 4x washing was performed using TBS-T (as phosphate can inhibit the 
alkaline phosphatase reaction), and detection performed using p-nitrophenyl phosphate 
substrate (Sigma). The plates were read at 405nm after 30 minutes.  
 










Radioactive labeling and PET/CT imaging  
Radioactive labeling was carried out, as described in the Chapter 2 methods section. The 
sprayed dose was 0.200 mCu per animal. Imaging sessions occurred at 1 hour, 4 hours, 
24 hours, 48 hours, and 72 hours post administration.  
 
Explant challenge with SHIV 
24 and 72 hours post transfection, biopsies from cervical and vaginal mucosa were 
removed. To mitigate the potential for sampling error, the extracted tissue was screened 
for the presence of PGT121-NanoLuc by reading the luminescence after NanoLuc 
substrate addition. Tissues were then washed 3x with 1x PBS, incubated with SHIV at a 
1:1 dilution for 2 hours at 37°C, washed a further 3x, then cultured on collagen sponges 
in 10% FBS supplemented DMEM media. Supernatant from the cultures was collected at 
the indicated timepoints and frozen, until p27 ELISA results could be attained.  
 
Ethics 
All sheep work was conducted with the written approval of the IACUC at Mississippi State 
University College of Veterinary Medicine and the Georgia Institute of Technology. All non-
human primate work was completed and with the written consent of the IACUC at the New 






















A long-term goal of the PET/CT vaccine tracking platform (Chapter 2 and 3) would be in 
developing a model by which the acute trafficking patterns of a vaccine could predict the 
development of vaccine correlates of protection and efficacy. A successful vaccine will 
stimulate the innate immune system and this theoretically should increase the amount of 
mRNA that reaches secondary lymphoid organs because of active cell transport, 
assuming that active cellular transport of mRNA correlates with immune cell stimulation 
and development of adaptive immune responses. In our study, we did observe the 
development of immune responses (see below for more information). In these same 
animals, we also observed the majority of mRNA that trafficked to draining lymph nodes 
at 24 hours had already done so at 4 hours. This fast trafficking of mRNA from the injection 
site is most likely due to passive transport by convective forces (as the cellular APCs take 
on the order of hours to be recruited to the injection site), but the time point of 4 hours is 
a bit nebulous. 
 
The transport of vaccine components to secondary lymphoid tissue can occur in a passive 
manner that is driven by convective forces or in an active, cell mediated manner by antigen 
presenting cells that infiltrate the tissue due to cytokine and chemokine signaling gradients 
brought about by inflammation. Passive convection occurs minutes to hours after delivery, 
while active transport is on the order of hours to days. In the next animal we perform this 
experimental approach with, we will image via PET/CT at 20 minutes, 1 hour, and 2 hours 
after administration. This quick series of images should help elucidate the contribution of 
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passive trafficking to the overall accumulation of mRNA at draining lymph nodes, as 
immune cell migration should not occur within the first 2 hours of vaccine administration.  
 
Correlating the downstream development of correlates of protection with the acute 
trafficking patterns after administration would be a powerful tool for vaccine development. 
Performing a study to examine whether PET/CT could be used to predict vaccine efficacy, 
would require a large number of animals. In the study of chapter 2, we monitored whether 
we could detect a humoral response to prME yellow fever antigen after boosting the 2 
non-human primates that remained alive after PET imaging. No antibodies were detected 
up to three months after giving the mRNA boost. The primary goal of the experiment was 
not to examine or evaluate vaccine efficacy. In fact, using similar doses in other studies 
has not elicited adaptive immune responses either. This is most likely the result of the low 
amount of mRNA that we used (200ug), the possibility that the antigen prME is not the 
most immunogenic, and perhaps due to the carrier CholK itself, which might not contain 
enough intrinsic innate stimulation to promote the development of adaptive immune 
responses with this antigen.  
 
By using specifically chosen vaccines that have differential efficacy when different routes 
of administration and/or adjuvants are used, we could examine how each parameter 
impacts: vaccine trafficking after administration, vaccine efficacy, and ultimately the 
relationship between the two.  The results of the study could prove useful in elucidating 
mechanisms of successful vaccines, save resources and animals, and provide a fast 
indication as to whether the vaccine will prove effective in that patient, instead of having 











Our immediate goal is to ascertain funding for a non-human primate mRNA-expressed 
PGT121 challenge study with SHIV. While quantifying antibody concentrations over time 
is useful from a scientific standpoint, the definitive test is to try to infect monkeys at 
different time points post FRT transfection with a combination of secreted and anchored 
PGT121 mRNA. If such a challenge demonstrates efficacy, then further studies can go 
back attempt to optimize parameters such as antibody type and the nature of the GPI 
membrane anchor. At the same time, an optimal sprayer can be specifically designed for 
use in rhesus macaques.  
 
The Bill and Melinda Gates Foundation has expressed interest in the FRT mRNA 
transfection platform for the purposes of contraception. This option will be explored 
through the use of antibody based binding to sperm and peptide-based spermicides.  
 
I am excited for the translational potential of this FRT platform – demonstrating expression 
in both sheep and rhesus macaques suggests that such an approach might also work on 
human tissue. The work presented in this thesis paves the way for numerous avenues of 
future research. While not all were enumerated here, numerous grants will be written in 




Future funding submissions will address the following:  
1. Aerosolized mRNA vaccine against HIV using gp120 mutational library  
2. Peripartum transmission of infectious diseases from mother to child 




I will address each of these concepts, briefly, in turn.  
 
 
1. Aerosolized mRNA vaccine against HIV using gp120 mutational library 
 
The coalescing of each chapter of my thesis points towards a fundamental framework with 
which to study the development of an mRNA based HIV vaccine. In Chapter 2, I described 
an approach to adjuvant naked mRNA vaccines by directly tethering the adjuvant to the 
mRNA molecule in an orthogonal manner. This resulted in antigen specific humoral and 
cellular responses in a mouse model to the protein encoded by the mRNA, in this case, 
the model antigen OVA. In Chapter 3, we developed a non-invasive means to monitor 
mRNA biodistribution after delivery.  Using an orthogonal oligo based method to 
radioactively label mRNA, we followed mRNA via PET/CT imaging in non-human primates 
as it aggregated in draining lymph nodes. As the mRNA was labeled directly, this approach 
is flexible, and is in fact currently being investigated for use in lipid nanoparticles to assay 
nucleic acid delivery and expression kinetics.  
 
In the first two chapters, the mRNA was delivered I.M., the most common route for vaccine 
administration worldwide. Chapter 4 presented an off the shelf, cost effective, and robust 
cervicovaginal aerosolized mucosal mRNA transfection platform that resulted in stable 
expression of the protein of interest in the lower FRT epithelium and genital secretions. 
We decided to utilize the PET/CT mRNA tracking approach described in Chapter 3, and 
the data suggests that at 1-hour post administration, mRNA is already exiting the region 
of the FRT and travelling to secondary lymphoid organs. Notably, mRNA was retained in 




With these tools at our disposal, we believe it is worth pursuing the use of an adjuvanted 
aerosolized mRNA vaccine based HIV vaccine. Vaginally delivered mRNA should mirror 
the early stages of HIV infection: diffusion through the epithelium, protein expression 
locally, and systemic ‘seeding’ of regional lymphoid organs. The innate immune sensors 
that detect viral mRNA (see Chapter 2) are many of the same that respond to IVT mRNA. 
Additionally, host mRNA translation will result in native glycosylation patterns and protein 
folding, as would occur during natural HIV infection. 
 
Our approach aims to address the huge problem in HIV vaccination of rapid virus evolution 
that HIV undergoes as it responds to host selective pressures. All broadly neutralizing 
antibodies tested in vivo demonstrate escape mutations from the virus. As the host 
immune response evolves to fight HIV, it remains one step behind the virus.  
 
We propose to create an mRNA library of all possible gp120 amino acid mutations. This 
early exposure of HIV envelope permutations could allow the development of rapid 
memory responses against potential HIV mutations during the course of early infection, or 
founder virus variants. After repeated dosing regimens, cellular and humoral immunity will 
be assessed.  
 
 
2. Peripartum transmission of infectious diseases from mother to child 
 
Our data demonstrates that within 4 hours post aerosol transfection, genital secretions of 
rhesus macaques contain neutralizing concentrations of PGT121. This acute expression 
opens up the possibility for urgent and emergency purposes. One such application is the 
prevention of peripartum transmission of infectious diseases. During labor, viral and 
bacterial pathogens within the FRT can inoculate the newborn through penetration of 
orifices and skin. Over the following week (and varying by pathogen), the pathogens are 
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able replicate until disease manifestations become clinically apparent. In the worst cases 
(HSV and Group B strep), encephalitis can lead to death of the newborn. If the infection 
status is suspected in the mother, the risk of peripartum transmission is almost nullified by 
appropriate antiviral and antibiotic regimens. The catch is that these approaches take on 
the order of days before these systemic drugs are able to reach the mucosal tissue where 
they can reduce pathogen burden in time for delivery. The current therapy standard also 
involves actively monitoring the newborn for signs of disease and delivering appropriate 
medicines, but this also requires prior awareness of motherly infection. Relevant 
pathogens in this regard are HIV, HSV, Group B strep, Dengue, and Hepatitis B.  
 
It is also feasible that our approach could be incorporated in the context of an emergency 
‘rape kit’. In such a use, the administered mRNA could encode a cocktail of sexual 
transmitted infection diseases (ie HSV, Hep B, HIV, HPV) and include a spermicide to 
prevent fertilization.  
 
 
3. Gene editing of the cervix for latent virus removal and cancer prevention 
 
The recent advent of CRISPR/Cas9 as a flexible gene-editing platform has led to rapid 
scientific developments. The system is modular and does not require molecular evolution, 
as was the case with previous gene editing techniques, such as zinc fingers nucleases 
and TALENs. The platform is comprised of two components: 1) a set of core nucleases, 
the most popular being spCas9 (streptococcus pyogenes), that were discovered within 
bacteria as an adaptive means to combat phages; and 2) guideRNAs (gRNAs) that are 
complementary to specific sequences of genomic DNA. The Cas9 nuclease associates 
with gRNAs to form active ribonucleoproteins (RNP). These RNPs translocate to the 
nuclease. Once in the nucleus, complementary gRNA annealing allows Cas9 to create 
double stranded breaks in the genome. Subsequent inherent repair mechanisms lead to 
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insertions and deletions from the wild type genome. As a result, output from gene editing 
experiments is reported as % of InDels (standing for insertion-deletions).  
 
We believe gene editing of the FRT mucosal could be leveraged to protect the cervix from 
tumor developing mutations and/or remove latent virus (HPV, HSV2, HIV). We will explore 
the use of aerosolized delivery as a gene-editing platform. As a topical note, CRISPR 
induced genetic mutations in rhesus macaques have been presented, but not published, 
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